EP0901368B1 - Dermal penetration enhancers and drug delivery systems involving same - Google Patents

Dermal penetration enhancers and drug delivery systems involving same Download PDF

Info

Publication number
EP0901368B1
EP0901368B1 EP97904304A EP97904304A EP0901368B1 EP 0901368 B1 EP0901368 B1 EP 0901368B1 EP 97904304 A EP97904304 A EP 97904304A EP 97904304 A EP97904304 A EP 97904304A EP 0901368 B1 EP0901368 B1 EP 0901368B1
Authority
EP
European Patent Office
Prior art keywords
skin
drug delivery
penetration enhancer
dermal
dermal penetration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97904304A
Other languages
German (de)
French (fr)
Other versions
EP0901368A4 (en
EP0901368A1 (en
Inventor
Barry Leonard Reed
Timothy Matthias Morgan
Barrie Charles Finnin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acrux DDS Pty Ltd
Original Assignee
Acrux DDS Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to AUPN8144A priority Critical patent/AUPN814496A0/en
Priority to AUPN8144/96 priority
Application filed by Acrux DDS Pty Ltd filed Critical Acrux DDS Pty Ltd
Priority to PCT/AU1997/000091 priority patent/WO1997029735A1/en
Publication of EP0901368A1 publication Critical patent/EP0901368A1/en
Publication of EP0901368A4 publication Critical patent/EP0901368A4/en
Application granted granted Critical
Publication of EP0901368B1 publication Critical patent/EP0901368B1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3792458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0901368(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/02Cosmetics or similar toilet preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/046Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/445Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/122Foams; Dry foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying, e.g. spreading, media, e.g. remedies, on the human body
    • A61M35/003Portable hand-held applicators having means for dispensing or spreading integral media
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/946Penetrant or absorbent, increases or enhances penetration into subject treated
    • Y10S514/947Topical application
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/974Containing designated ingredient to reduce noxious effects of active ingredient, e.g. taste masking, odor reducing

Abstract

A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.

Description

  • The present invention relates to percutaneous or transdermal drug delivery. More specifically, the invention relates to the use of a non-occlusive, percutaneous or transdermal drug delivery system.
  • According to the invention, transdermal drug formulations may be used for local application or systemic delivery.
  • The prevention or treatment of local or topical disease states or conditions of the skin has traditionally used simple non-occlusive delivery systems. These drug delivery systems usually include a volatile and/or non-volatile medium whereby a composition of the drug and medium is topically applied to the skin, generally in the vicinity of or directly on the area of skin to be treated. Such delivery systems usually take the form of emulsions, creams, ointments, foams, gels, liquids, sprays and aerosols. These delivery systems are generally used to treat skin inflammations, soft-tissue contusions, parasites, fungal and bacterial topical infection and topical analgesia. The limitation with this type of delivery system is that systemic drugs are generally not suitable for this type of administration. Some major problems with the current state of the art relate to a lack of efficacy of systemic drugs because of the low drug flux across the skin, as observed for drugs such as testosterone, amlodipine, fentanyl, buprenorphine and many others. Other drugs, such as gLyceryl trinitrate, Nitrobid™ (a drug for the treatment of angina), are difficult to deliver by these systems due to the inability to adequately control the rate of drug delivery, or the requirement for a very large application area. Other problems with the poor dermal penetration of drugs is that the drug can be easily washed off or transferred to clothes, other surfaces or other animals.
  • The dermal delivery of drugs may represent the oldest form of drug delivery in human history. Resins and animal fats were probably used by humans in early times to treat damage to the skin resulting from injuries and burns. Such substances for local delivery of active substances remained largely unchanged until as late as this century. The concept of transdermal systemic drug delivery was first seriously advocated by Dr Alejandro Zaffaroni in US patent Nos. 3,598,122, 3,731,683 and 3,797,494 from the early 1970s. Transdermal systemic drug delivery provides an effective method of achieving improved bioavailability for physiologically active substances where the drugs are poorly absorbed by traditional routes of delivery. It can also be used where oral dosing is poorly tolerated or not possible.
  • Transdermal formulations are however limited. For example polar drugs tend to penetrate the skin too slowly. Since most drugs are of a polar nature this limitation is significant, as is the fact that many drugs cause irritation at the site of topical application.
  • Two main methods are known for assisting the rate of penetration of drugs across the skin. The first is to increase the thermodynamic activity of the drug. The thermodynamic activity of a drug in a dermal formulation is proportional to the concentration of the drug and the selection of the vehicle. According to the laws of thermodynamics, the maximum activity of a drug is related to that of the pure drug crystal. The second method involves the use of compounds known as penetration enhancers to increase the permeability of the dermal surface and has generally proven to be more convenient and effective.
  • Since the early 1970s the main focus of transdermal systemic drug delivery has been, and still is, on transdermal patch devices. These patch devices are like bandages which are attached to the surface of intact skin for prolonged periods of time to allow a desired systemic delivery of a drug or other physiologically active agent. These transdermal patch devices occlude the skin and trap the drug, together with volatiles and vehicle excipients, between the skin and an outer impermeable backing membrane. The membrane prevents the evaporation or diffusion of vehicle excipients, volatiles and drug into an environment other than the target skin site. The prolonged length of time required for transfer of the drug and excipients from the patch into the skin can and often does result in local skin irritation. The irritation is caused by prolonged contact on the skin by the drug, volatiles, vehicle excipients, or the adhesive used to attach the patch device to the skin. The occlusive nature of the patch device also restricts the natural ability of the skin to "breathe", increasing the risk of irritation. With added problems of complex and costly manufacturing processes for transdermal patch devices there is a need for improved transdermal drug delivery systems.
  • The rate of drug delivery across a dermal surface can be increased by dermal penetration enhancers. The problem with most known dermal penetration enhancers is that they are often toxic, irritating or allergenic. These enhancers tend to be proton accepting solvents such as dimethylsulfoxide and dimethyacetamide. More recently, 2-pyrrolidine, N,N-diethyl-m-toluamide (Deet), 1-dodedal-azacycloheptane-2-one (Azone®), N,N-dimethylformamide, N-methyl-2-pyrrolidine and calcium thioglycolate have been reported as effective enhancers. However, difficulties remain with such dermal enhancers because the problem of irritation at the site of application has not been overcome.
  • The most critical problem with these compounds however is their toxicity. If a compound when used as a dermal enhancer is toxic, irritating or allergenic, then that compound is unsuitable for application to the animal body. Dimethyl sulfoxide and dimethyl acetamide are not clinically acceptable for these reasons. Although Deet and Azone® have lower reported toxicities, their toxicity is still such that they are not widely used. It is possible that Azone® may be employed as a dermal penetration enhancer if the amount applied is sufficiently small so as not to be appreciably toxic, irritating or allergenic to the animal.
  • The thermodynamic activity of a drug can be increased by employing supersaturated systems which give rise to unusually high thermodynamic potentials [Coldman, et al., J. Pharm. Sci., 58(9), 119, 1969]. However, topical vehicles relying on supersaturation, have the major limitation of formulation instability, both prior to and during application to the skin. As such, they are of limited clinical value within a non-occlusive volatile:non-volatile delivery vehicle, because as soon as the formulation comes into contact with a person's clothing or the like, the drug often precipitates; hence the formulation is no longer supersaturated and any enhanced percutaneous absorption ceases.
  • Other workers such as Kondo, et al., [J. Pharmacobio-Dyn., 10, 743, 1987] who were using supersaturation to achieve enhanced transdermal drug delivery, have relied on the use of anti-nucleating polymers to stabilize the formulation. However, the applied drug formulations stabilised with polymers formed an appreciable surface mass on the skin which remained there over a prolonged duration of many hours, not a few minutes. So while Kondo advocated the use of a metered spray to deliver these formulations, in reality it would be impossible to obtain a non-occlusive delivery system with a short application time and still maintain a clinically useful transdermal penetration enhancement.
  • German patent application DE 4334553-A1 to Jenapharm GmbH discloses a pharmaceutical liquid system consisting of a drug (diclofenac), a lipophilic phase, a volatile component and appropriate antioxidants, preservatives or stabilisers. This system relies on supersaturation to increase the flux rate of dermal absorption. An application chamber is used to prevent accidental precipitation of the supersaturated drug delivery system over the application time of 150 minutes.
  • Japanese patent JP 61-268631 to Showa Denko KK discloses dermal penetration enhancers suitable for use with water-soluble drugs. The dermal penetration enhancers disclosed include 1-5 carbon fatty acid esters of para-aminobenzoic acid but their chemical structures are quite distinct from the compounds used in the present invention, and the physicochemical properties of the 1-5 carbon fatty acid esters of para-aminobenzoic acid are markedly different to those to be used according to the present invention. For example the octanol-water partition coefficients for all the 1-5 carbon fatty acid esters of para-aminobenzoic acid are at least 200 fold lower than those of the present invention. Also the preferred dermal penetration enhancer disclosed in JP 61-268631 is the 2 carbon fatty acid ester of para-aminobenzoic acid (or Benzocaine) which has an octanol-water partition coefficient which is more than 8000 fold lower than those of the present invention. Unlike those of the present invention, the preferred dermal penetration enhancer disclosed in JP 61-268631 has significant pharmacological properties in that it is a local anaesthetic, which has also been reported to cause irritant and allergic skin reactions. The compounds used in the present invention fulfil the ideal properties of a dermal penetration enhancer in that they are non-irritant and pharmacologically inert [Barry, B. W. Vehicle Effect: What Is an Enhancer? In: Topical Drug Bioavailability, Bioequivalence, and Penetration. Shah, V. P.; Maibach, H. I. Eds. Plenum Press: New York, 1993; pp 261-276.].
  • It was not surprising then to find that in previous studies [Feldmann, et al., Arch. Derm., 94, 649, 1996; Coldman, et al., J. Pharm. Sci., 58(9), 119, 1969; and Bhatt, et al., Int. J. Pharm., 50, 157, 1989] where low volumes of non-occlusive volatile:non-volatile vehicles had been applied to the skin, the extent of drug delivery was very limited. To date the only formulations that have been employed clinically are either for local therapies, such as topical minoxidil and topical non-steroidal antiinflammatories, or for transdermal drug delivery of compounds which readily diffuse across the skin such as glyceryl trinitrate and isosorbide dinitrate. As the permeability coefficient of sex hormones, for example, are an order of magnitude lower than glyceryl trinitrate, a marked penetration enhancement effect would be needed to achieve clinically acceptable transdermal drug delivery.
  • It is desirable to have a clinically acceptable non-occlusive transdermal drug delivery system where the drug and penetration enhancer undergoes rapid partitioning into the skin to allow a convenient application time, leaving no residual formulation on the skin surface, and maintaining good substantivity within the skin. These characteristics can overcome problems such as a loss of drug penetration or possibly a transfer of the drug from the treated individual to another upon intimate contact, such as that observed for a testosterone ointment being used for a male patient, but which caused virilization in his female sexual partner [Delance, et al. , Lancet, 1, 276, 1984].
  • EP-A-0189861 discloses percutaneous absorption accelerators for ionic water-soluble medicines comprising ionic oil-soluble substances and their salts, amphoteric surfactants and/or non-ionic substances. The compositions disclosed are in the form of films, gels, ointments or poultices.
  • EP-A-552405 discloses a percutaneous absorption promoter, a tape plaster and a method for promoting percutaneous absorption. The document specifically discloses compositions comprising anthranilic acid derivatives in a 50% aqueous solution of ethanol. The significant proportion of water results in a non -volatile carrier and the composition is designed to be used as an occlusive system with a plaster.
  • US 4,663,157 discloses sunscreen compositions comprising sunscreen esters. The compositions disclosed in this document are not drug delivery systems as the compositions do not comprise a drug or prodrug.
  • It is an object of the present invention to overcome or at least alleviate one or more of the abovementioned disadvantages of the prior art systems.
  • According to a first aspect of the present invention there is provided the use of a non-occlusive, percutaneous or transdermal drug delivery system which comprises:
    • (i) an effective amount of at least one physiologically active agent which is a drug, or prodrug thereof;
    • (ii) at least one non-volatile dermal penetration enhancer; and
    • (iii)at least one volatile liquid;
    wherein the dermal penetration enhancer is one or more of octyl dimethyl-para-aminobenzoate, octyl paramethoxycinnamate or octyl salicylate.
  • The present inventors have found a new class of dermal penetration enhancers being skin-tolerant ester sunscreens, which are generally considered safe by the FDA (US). Compounds such as octyl dimethyl-para-aminobenzoate (Padimate O) and octyl salicylate have been extensively used over the last ten to twenty years as safe and effective sunscreens in concentrations up to 8 % v/v for Padimate O and 5% v/v for octyl salicylate.
  • According to the invention the drug delivery systems may comprise any physiologically active agent which is a drug or prodrug thereof together with the penetration enhancer incorporated into a dosage form for topical application to the skin or mucous membranes of animals. Suitable dosage forms include creams, lotions, gels, ointments, suppositories, mousses, spray, for example nasal sprays, aerosols, buccal and sublingual tablets, or any one of a variety of transdermal devices for use in the continuous administration of systematically active drugs by absorption through the skin, oral mucosa or other membranes. Some examples of suitable vehicles are given in US Patent Nos. 3,598,122, 3,598,123, 3,742,951, 3,814,097, 3,921,636, 3,993,072, 3,993,073, 3,996,934, 4,031,894, 4,060,084, 4,069,307, 4,201,211, 4,230,105, 4,292,299, 4,292,303, 5,323,769, 5,013,085, 5,474,783, 4,941,880 and US Pat. No. 4,077,407. These patents also disclose a variety of specific systematically active agents which may also be useful in transdermal delivery in adjunct to those of this invention.
  • Physiologically active agents that may be used in the percutaneous or transdermal drug delivery system according to the present invention include any locally or systemically active agents which are drugs or prodrugs thereof and which are compatible with the dermal penetration enhancers and which can be delivered through the skin with the assistance of the dermal penetration enhancer to achieve a desired effect. These active agents (grouped by therapeutic class) include:
  • Cardiovascular system
  • Antihypertensives such as hydralazine, minoxidil, captopril, enalapril, clonidine, prazosin, debrisoquine, diazoxide, guanethidne, methyldopa, reserpine, trimetaphan.
    Calcium channel blockers such as diltiazem, felodopine, amlodipine, nitrendipine, nifedipine and verapamil.
    Antiangina agents such as glyceryl trinitrate, erythritol tetranitrate, pentaerythritol tetranitrate, mannitol hexanitrate, perhexilene, isosorbide dinitrate and nicorandil.
    Beta-adrenergic blocking agents such as alprenolol, atenolol, bupranolol, carteolol, labetalol, metoprolol, nadolol, nadoxolol, oxprenolol, pindolol, propranolol, sotalol, timolol and timolol maleate.
    Adrenergic stimulants such as adrenaline, ephedrine, fenoterol, isoprenaline, orciprenaline, rimeterol, salbutamol, salmeterol, terbutaline, dobutamine, phenylephrine, phenylpropanolamine, pseudoephedrine and dopamine.
    Vasodilators such as cyclandelate, isoxsuprine, papaverine, dipyrimadole, isosorbide dinitrate, phentolamine, nicotinyl alcohol, co-dergocrine, nicotinic acid, glyceryl trinitrate, pentaerythritol tetranitrate and xanthinol.
    Antimigraine preparations such as ergotamine, dihydroergotamine, methysergide, pizotifen and sumatriptan.
  • Drugs affecting blood and haemopoietic tissues.
  • Anticoagulants and thrombolytic agents such as warfarin, dicoumarol, low molecular weight heparins such as enoxaparin; streptokinase and its active derivatives.
    Haemostatic agents such as aprotinin, tranexamic acid and protamine.
  • Central nervous system
  • Analgesics, antipyretics including the opiod analgesics such as buprenorphine, dextromoramide, dextropropoxyphene, fentanyl, alfentanil, sufentanil, hydromorphone, methadone, morphine, oxycodone, papaveretum, pentazocine, pethidine, phenoperidine, codeine and dihydrocodeine. Others include acetylsalicylic acid (aspirin), paracetamol, and phenazone.
  • Hypnotics and sedatives such as the barbiturates, amylobarbitone, butobarbitone and pentobarbitone and other hypnotics and sedatives such as choral hydrate, chlormethiazole, hydroxyzine and meprobamate.
    Antianxiety agents such as the benzodiazepines, alprazolam, bromazepam, chlordiazepoxide, clobazam, chlorazepate, diazepam, flunitrazepam, flurazepam, lorazepam, nitrazepam, oxazepam, temazepam and triazolam.
    Neuroleptic and antipsychotic drugs such as the phenothiazines, chlorpromazine, fluphenazine, pericyazine, perphenazine, promazine, thiopropazate, thioridazine and trifluoperazine and the butyrophenones, droperidol and haloperidol and the other antipsychotic drugs such as pimozide, thiothixene and lithium.
  • Antidepressants such as the tricyclic antidepressants amitryptyline, clomipramine, desipramine, dothiepin, doxepin, imipramine, nortriptyline, opipramol, protriptyline and trimipramine and the tetracyclic antidepressants such as mianserin and the monoamine oxidase inhibitors such as isocarboxazid, phenelizine, tranylcypromine and moclobemide and selective serotonin re-uptake inhibitors such as fluoxetine, paroxetine, citalopram, fluvoxamine and sertraline.
  • CNS stimulants such as caffeine.
  • Anti-alzheimer's agents such as tacrine.
  • Antiemetics, antinauseants such as the phenothiazines, prochloperazine, thietliylperazine and 5HT-3 receptor antagonists such as ondansetron and granisetron and others such as dimenhydrinate, diphenhydramine, metoclopramide, domperidone, hyoscine, hyoscine hydrobromide, hyoscine hydrochloride, clebopride and brompride.
  • Musculoskeletal system
  • Non-steroidal anti-inflammatory agents including their racemic mixtures or individual enantiomers where applicable, such as ibuprofen, flurbiprofen, ketoprofen, aclofenac, diclofenac, aloxiprin, aproxen, aspirin, diflunisal, fenoprofen, indomethacin, mefenamic acid, naproxen, phenylbutazone, piroxicam, salicylamide, salicylic acid, sulindac, desoxysulindac, tenoxicam, tramadol and ketoralac.
  • Additional non-steroidal antiinflammatory agents which can be formulated in combination with the dermal penetration enhancers include salicylamide, salicylic acid, flufenisal, salsalate, triethanolamine salicylate, aminopyrine, antipyrine, oxyphenbutazone, apazone, cintazone, flufenamic acid, clonixeril, clonixin, meclofenamic acid, flunixin, colchicine, demecolcine, allopurinol, oxypurinol, benzydamine hydrochloride, dimefadane, indoxole, intrazole, mimbane hydrochloride, paranylene hydrochloride, tetrydamine, benzindopyrine hydrochloide, fluprofen, ibufenac, naproxol, fenbufen, cinchophen, diflumidone sodium, fenamole, flutiazin, metazamide, letimide hydrochloride, nexeridine hydrochloride, octazamide, molinazole, neocinchophen, nimazole, proxazole citrate, tesicam, tesimide, tolmetin, and triflumidate.
    Muscle relaxants such as baclofen, diazepam, cyclobenzaprine hydrochloride, dantrolene, methocarbamol, orphenadrine and quinine.
  • Hormones and Steroids
  • Oestrogens such as oestradiol, oestriol, oestrone, ethinyloestradiol, mestranol, stilboestrol, dienoestrol, epioestriol, estropipate and zeranol.
    Progesterone and other progestagens such as allyloestrenol, dydrgesterone, lynoestrenol, norgestrel, norethyndrel, norethisterone, norethisterone acetate, gestodene, levonorgestrel, medroxyprogesterone and megestrol.
    Antiandrogens such as cyproterone acetate and danazol. Antioestrogens such as tamoxifen and epitiostanol and the aromatase inhibitors, exemestane and 4-hydroxy-androstenedione and its derivatives.
    Androgens and anabolic agents such as testosterone, methyltestosterone, clostebol acetate, drostanolone, furazabol, nandrolone oxandrolone, stanozolol, trenbolone acetate, dihydrotestosterone, 17-α-methyl-19-nortestosterone and fluoxymesterone.
    5-alpha reductase inhibitors such as finasteride, turosteride, LY-191704
  • Further examples of steroidal antiinflammatory agents for use in the instant compositions include include cortodoxone, fluoracetonide, fludrocortisone, difluorsone diacetate, flurandrenolone acetonide, medrysone, ameinafel, amcinafide, betamethasone and its other esters, chloroprednisone, clorcortelone, descinolone, desonide, dichlorisone, difluprednate, flucloronide, flumethasone, flunisolide, flucortolone, fluoromethalone, fluperolone, fluprednisolone, meprednisone, methylmeprednisolone, paramethasone, cortisone acetate, hydrocortisone cyclopentylpropionate, cortodoxone, flucetonide, fludrocortisone acetate, flurandrenolone acetonide, medrysone, amcinafal, amcinafide, betamethasone, betamethasone benzoate, chloroprednisone acetate, clocortolone acetate, descinolone acetonide, desoximetasone, dichlorisone acetate, difluprednate, flucloronide, flumethasone pivalate, flunisolide acetate, fluperolone acetate, fluprednisolone valerate, paramethasone acetate, prednisolamate, prednival, triamcinolone hexacetonide, cortivazol, formocortal and nivazol.
    Thyroid hormones such as calcitonin, thyroxine and liothyronine and antithyroid agents such as carbimazole and propylthiouracil.
    Ovulation inducers such as clomiphene.
  • Genitourinary system
  • Diuretics such as the thiazides, related diuretics and loop diuretics, bendrofluazide, chlorothiazide, chlorthalidone, dopamine, cyclopenthiazide, hydrochlorothiazide, indapamide, mefruside, methycholthiazide, metolazone, quinethazone, bumetanide, ethacrynic acid and frusemide and pottasium sparing diuretics, spironolactone, amiloride and triamterene.
    Antidiuretics such as desmopressin, lypressin and vasopressin including their active derivatives or analogs.
  • Antimalarials such as primaquine, pyrimethamine, chloroquine, hydroxychloroquine, quinine, mefloquine and halofantrine.
  • Antiviral agents such as acyclovir and acyclovir prodrugs, famciclovir, zidovudine, didanosine, stavudine, lamivudine, zalcitabine, saquinavir, indinavir, ritonavir, n-docosanol, tromantadine and idoxuridine.
  • Cytotoxic agents such as plicamycin, cyclophosphamide, dacarbazine, fluorouracil and its prodrugs [described,for example, in International Journal of Pharmaceutics 111, 223-233 (1994)], methotrexate, procarbazine, 6-mercaptopurine and mucophenolic acid.
  • Metabolism
  • Anorectic and weight reducing agents including dexfenfluramine, fenfluramine, diethylpropion, mazindol and phentermine.
  • Respiratory system
  • Antitussives such as ethylmorphine, dextromethorphan and pholcodine. Expectorants such as acetylcysteine, bromhexine, emetine, guaiphenesin, ipecacuanha ans saponins.
    Decongestants such as phenylephrine, phenylpropanolamine ans pseudoephedrine.
    Bronchospasm relaxants such as ephedrine, fenoterol, orciprenaline, rimiterol, salbutamol, sodium cromoglycate, cromoglycic acid and its prodrugs [described,for example, in International Journal of Pharmaceutics 7, 63-75 (1980)], terbutaline, ipratropium bromide, salmeterol and theophylline and theophylline derivatives.
  • Allergy and immune system
  • Local anaesthetics such as bupivacaine, amethocaine, lignocaine, cinchocaine, dibucaine, mepivacaine, prilocaine and etidocaine.
  • Neuromuscular blocking agents such as suxamethonium, alcuronium, pancuronium, atracurium, gallamine, tubocurarine and vecuronium.
  • Psychicenergisers, such as 3-(2-aminopropyl)indole, 3-(2-aminobutyl)indole, and the like.
  • The active agent and penetration enhancer are delivered by simultaneous administration.
  • Preferably the animal to which the drug or prodrug is to be administered is a human but the invention also extends to administration to non-human animals.
  • Preferably the non-occlusive drug delivery system is not supersaturated with respect to the drug or prodrug. As the volatile liquid of the non-occlusive drug delivery system evaporates, the resulting non-volatile composition is rapidly driven into the dermal surface or mucosal membrane. It is possible that as the volatile liquid evaporates, the non-volatile dermal penetration enhancer becomes supersaturated with respect to the active agent. However, it is preferred that any supersaturation does not occur before transport of the resulting non-volatile composition across the epidermal surface has occurred.
  • It is most desirable that, after application of the non-occlusive, percutaneous or transdermal drug delivery system, the volatile component of the delivery system evaporates and the area of skin to which the drug delivery system was applied becomes touch dry. Preferably the are of skin becomes touch-dry within 3 minutes, most preferably within 1 minute.
  • The group of dermal penetration enhancing ester sunscreen compounds of the drug delivery systems used according to the present invention are particularly suitable for non-occlusive transdermal delivery of active agents through the skin and membranes of an animal. These dermal penetration enhancing compounds are of low toxicity to the skin and are excellent promoters of percutaneous and oral mucosal (especially gingival) absorption.
  • Preferred volatile liquids of the present invention include safe skin-tolerant solvents such as ethanol and isopropanol. An aerosol propellant, such as dimethyl ether, may constitute a volatile liquid for the purpose of the present invention.
  • Surprisingly the group of dermal penetration compounds identified enhance the absorption of active agents and prodrugs thereof through the skin and mucous membranes while avoiding the significant pharmacological disadvantages, and toxicities of prior art enhancers. Additionally the group of compounds used in the drug delivery systems according to the invention surprisingly exhibit appreciable penetration into and substantivity for the outer layers of the skin, namely the stratum corneum which has previously presented a formidable barrier to percutaneous drug absorption.
  • In drug delivery systems used according to the present invention a pharmaceutical compounding agent, co-solvent, surfactant, emulsifier, antioxidant, preservative, stabiliser, diluent or a mixture of two or more of said components may be incorporated in these systems as is appropriate to the particular route of administration and dosage form. The amount and type of components used should be compatible with the dermal penetration enhancers as well as with the active ingredient. A co-solvent or other standard adjuvant, such as a surfactant, may be required to maintain the agent in solution or suspension at the desired concentration.
  • The pharmaceutical compounding agents can include paraffin oils, esters such as isopropyl myristate, ethanol, silicone oils and vegetable oils. These are preferably used in the range 1 to 50% . Surfactants such as ethoxylated fatty alcohols, glycerol mono stearate, phosphate esters, and other commonly used emulsifiers and surfactants preferably in the range of 0.1 to 10 % may be used, as may be preservatives such as hydroxybenzoate esters for preservation of the compound preferably in amounts of 0.01 % to 0.5 %. Typical cosolvents and adjuvants may be ethyl alcohol, isopropyl alcohol, acetone, dimethyl ether and glycol ethers such as diethylene glycol mono ethyl ether. These may be used in amounts of 1 to 50 % .
  • In drug delivery systems used according to the invention, whilst a pharmaceutical compounding agent, co-solvent, surfactant, emulsifier, antioxidant, preservative, stabiliser, diluent or a mixture of two or more of said components may be incorporated; these must be compatible with the ability of the system to become touch-dry after application.
  • Because of the effect of the penetration enhancer, the dosage of the physiologically active agent may often be less than that conventionally used. It is proposed that, a dosage near the lower end of the useful range of the particular agent may be employed initially and increased as indicated from the observed response if necessary.
  • The concentration of physiologically active agent used in the drug delivery system will depend on its properties and may be equivalent to that normally utilised for the particular agent in conventional formulations. Both the amount of physiologically active agent and the amount of penetration enhancer will be influenced by the type of effect desired. For example, if a more localised effect is required, lower amounts of physiologically active agents and lower concentrations of enhancer may be appropriate. Where deeper penetration is desired, as in the case of local anaesthesia, a higher concentration of enhancer may be appropriate.
  • Where it is desired to achieve systemic concentration of an agent, proportionately higher concentrations of the enhancer may be required in the transdermal drug delivery system and the amount of active substance included in the composition should be sufficient to provide the blood level desired.
  • The concentration of absorption/penetration enhancer may be in the range from 10-10,000 weight percent of absorption/penetration enhancer based upon the weight of active ingredient. The ratio of penetration enhancer to active ingredient may vary considerably and will be governed as much as anything, by the pharmacological results that are required to be achieved. In principle, it is desirable that as little absorption enhancer as possible is used. On the other hand, for some actives, it may well be that the upper range of 10,000 % by weight will be required. It is preferred that the penetration enhancer and active are in approximately equal proportions.
  • Surprisingly, it has been found that a large range of systemic drugs can be delivered to a subject in need thereof by the non-occlusive drug delivery system used in the present invention. That is, the drug delivery system delivers the physiologically active agent to a animal without the need for an occlusive patch device. The efficacy of known systemic drug delivery systems, and in particular transdermal patch devices is maintained, and in some cases is increased by use of non-occlusive, percutaneous or transdermal drug delivery systems in the present invention.
  • A particular advantage of the non-occlusive drug delivery system used in the present invention is that patient compliance is improved as the system does not occlude the skin or membrane and therefore local irritation and allergic sensitisation problems arising from prolonged exposure of the skin to both the delivery system of occlusive transdermal patch devices and the adhesive used to affix these patches to the skin are reduced.
  • The following definitions apply through this description and the claims which follow.
  • The term "mucous membrane" refers generally to any of the mucous membranes in the body, absorption through the mucous membranes of the oral cavity which is of particular interest. Thus, buccal, sublingual, gingival and palatal absorption are specifically contemplated by the present invention. In a preferred embodiment, the penetration enhancers of the present invention are used to improve absorption through those oral tissues which most resemble the skin in their cellular structure, i.e. the gingiva and palate.
  • The term "physiologically active agent" is used herein to refer to a broad class of useful chemical and therapeutic agents.
  • The term "physiologically active" in describing the agents contemplated herein is used in a broad sense to comprehend not only agents having a direct pharmacological effect on the host, but also those having an indirect or observable effect which is useful in the medical arts.
  • A "prodrug" of a physiologically active agent herein means a structurally related compound or derivative of an active compound which in the animal body is converted to the desired physiologically active compound. The prodrug itself may have little or none of the desired activity.
  • The terms "percutaneous" and "transdermal" are used herein in the broadest sense to refer to being able to pass through unbroken skin.
  • The term "dermal penetration enhancer" is used herein in its broadest sense to refer to an agent which improves the rate of percutaneous transport of active agents across the skin for use and delivery of active agents to organisms such as animals, whether it be for local application or systemic delivery.
  • The term "non-occlusive" is used herein in its broadest sense to refer to not trapping or closing the skin to the atmosphere by means of a patch device, fixed reservoir, application chamber, tape, bandage, sticking plaster, or the like which remains on the skin at the site of application for a prolonged length of time.
  • The term "stratum corneum" is used herein in its broadest sense to refer to the outer layer of the skin, which is comprised of (approximately 15) layers of terminally differentiated keratinocytes made primarily of the proteinaceous material keratin arranged in a 'brick and mortar' fashion with the mortar being comprised of a lipid matrix made primarily from cholesterol, ceramides and long chain fatty acids. The stratum corneum creates the rate-limiting barrier for diffusion of the active agent across the skin.
  • The term "skin-depot" is used herein in its broadest sense to refer to a reservoir or deposit of active agent and dermal penetration enhancer within the stratum corneum, whether it be intra-cellular (within keratinocytes) or inter-cellular.
  • The term "volatile:non-volatile liquid vehicle" is used in the art to refer to a liquid pharmaceutical vehicle comprising a volatile liquid mixed with a non-volatile liquid vehicle, such as a dermal penetration enhancer. A system or vehicle comprising a volatile liquid mixed with a non-volatile dermal penetration enhancer when described herein is used in its broadest sense to include those systems known as volatile:non-volatile liquid vehicles.
  • The non-occlusive, percutaneous or transdermal drug delivery system used according to the present invention enables a wide range of physiologically active agents to be delivered through the skin to achieve a desired systemic effect. The drug delivery system comprises the active agent intimately mixed with a non-volatile dermal penetration enhancer and a volatile liquid. Where the drug delivery system is applied to the skin, the active agent and non-volatile liquid are thermodynamically driven into the skin as the volatile liquid evaporates. Once within the skin the non-volatile liquid may either disrupt the lipid matrix and/or act as a solubilizer to allow an enhanced penetration rate of the active agent through the skin and into the subject being treated. In this way, the dermal penetration enhancer acts as a vehicle and many systemic active agents are able to be transdermally administered to an animal.
  • It is believed that the non-volatile dermal penetration enhancer is readily absorbed into the stratum corneum in sufficient quantities to form a reservoir or depot of the dermal penetration enhancer within the stratum corneum. The dermal penetration enhancer also contains the active agent to be administered and as the dermal penetration enhancer crosses through the skin to form the skin-depot, the active agent contained therein is transported through the skin and contained within the depot. These depots are believed to form within the lipid matrix of the stratum corneum wherein the lipid matrix creates a rate-limiting barrier for diffusion of the active agent across the skin and allows the dermally administered active agent to be systemically released over a period of time, usually up to 24 hours.
  • Once the volatile liquid of the non-occlusive drug delivery system has evaporated, driving the mixture of non-volatile dermal penetration enhancer and active agent into the stratum corneum, the outer surface of the skin is then substantially free of active agent and non-volatile dermal penetration enhancer. Normal touching, wearing of clothes, rinsing or even washing of the skin will not, to any significant extent, affect delivery of the drug or displace either the active agent or the non-volatile dermal penetration enhancer, once the volatile liquid has evaporated.
  • This is in contrast to prior-art systems where supersaturated solutions are used to increase the rate of drug permeation across the skin. Such supersaturated solutions are susceptible to ready precipitation and require stabilization, such as with polymers, or protection from external surfaces or objects which may effect nucleation.
  • The rate of absorption of the physiologically active agent via the stratum corneum is increased by the non-volatile dermal penetration enhancer. The active agent may be dissolved or suspended in the dermal penetration enhancer at the time when it is being transported from the surface of the skin and into the stratum corneum. The performance of the dermal penetration enhancer to deliver a desired active agent varies with differences in both the nature of the dermal penetration enhancer and active agent. It is understood that different dermal penetration enhancers may need to be selected to be appropriate for delivery of various active agents.
  • Physiologically active agents that may be used in the percutaneous or transdermal drug delivery system include any locally or systemically active agents which are drugs or prodrugs thereof and
    which are compatible with the non-volatile dermal penetration enhancers and volatile liquids and which can be delivered through the skin with the assistance of the dermal penetration enhancer to achieve a desired effect.
  • Preferred active agents include steroids and other hormone derivatives, more preferably testosterone, oestradiol, ethinyloestradiol, progesterone, norethisterone acetate and gestodene; and non-steroidal anti-inflammatory drugs, preferably ibuprofen, ketoprofen, flurbiprofen, naproxen and diclöfenac; and opioid analgesics, preferably fentanyl and buprenorphine; and antinauseants, preferably prochlorperazine, metochlopramide, ondansetron and scopolamine; and antioestrogens, preferably tamoxifen and epitiostanol and the aromatase inhibitors, preferably exemestane and 4-hydroxy-androstenedione and its derivatives; and 5-alpha reductase inhibitors, preferably finasteride, turosteride, LY191704 and anxiolytics, preferably alprazolam; and prostaglandins, preferably alprostadil and prostacylcin and their derivatives; and melatonin; and anti-virals, preferably n-docosanol, tromantadine and lipophilic pro-drugs of acyclovir; and low molecular weight heparin, preferably enoxaparin; and anti-migraine compounds, preferably sumatriptan; and antihypertensives, preferably clonidine, amlodipine and nitrendipine; and anti-malarials, preferably primaquine; and minoxidil and minoxidil prodrugs; and pilocarpine; and bronchodilators, preferably salbutamol, terbutaline, salmeterol; and anti-depressants, preferably ibogaine, bupropion and rolipram; and anti-alzheimer's agents, preferably fluphenazine and haloperidol; and anti-parkinson agents, preferably N-0923; and antiandrogens, preferably cyproterone acetate; and anorectic agents, preferably mazindol.
  • Diseases or conditions that may be treated by using the drug delivery system include, but are not limited to, male hormone replacement in testosterone deficient hypogonadal men, female hormone replacement therapy for postmenopausal women, androgen replacement therapy for females lacking libido, soft tissue injury, narcotic withdrawal, severe post-operative pain, motion sickness, oestrogen dependent breast cancer, prostatic enlargement and/or prostatic cancer, anxiety disorders, male impotence, Raynauds syndrome and varicose veins, sleep disorders herpes virus infections, deep vein thrombosis, migraine, high blood pressure, malaria, asthma, particularly nocturnal asthma, psychotic disorders, severe postnatal depression and obesity.
  • The foregoing lists are by no means intended to be exhaustive and any physiologically active agent that is a drug or prodrug thereof and that is compatible with the preferred volatile liquids and non-volatile dermal penetration enhancers of the drug delivery system may be applied by the method of the present invention to treat the disease or condition concerned.
  • The drug delivery system of the present invention may be applied to the skin by means of an aerosol, spray, pump-pack, brush, swab, or other applicator. Preferably, the applicator provides either a fixed or variable metered dose application such as a metered dose aerosol, a stored-energy metered dose pump or a manual metered dose pump. The application is most preferably performed by means of a topical metered dose aerosol combined with an actuator nozzle shroud which together accurately control the amount and/or uniformity of the dose applied. One function of the shroud is to keep the nozzle at a pre-determined height above, and perpendicular to, the skin or membrane to which the drug delivery system is being applied. This function may also be achieved by means of a spacer-bar or the like. Another function of the shroud is to enclose the area above the skin or membrane in order to prevent or limit bounce-back and/or loss of the drug delivery system to the surrounding environment. Preferably the area of application defined by the shroud is substantially circular in shape.
  • The drug delivery system may be propelled by either pump pack or more preferably by the use of propellants such as hydrocarbons, hydro fluorocarbons, nitrogen, nitrous oxide, carbon dioxide or ethers, preferably dimethyl ether. The non-occlusive, drug delivery system is preferably in a single phase system as this allows less complicated manufacture and ease of dose uniformity. It may also be necessary to apply a number of dosages on untreated skin to obtain the desired result.
  • The invention will now be described with reference to the following examples and accompanying drawings. The examples and drawings are not to be construed as limiting the invention in any way. They are included to further illustrate the present invention and advantages thereof.
  • In the drawings:
    • Fig. 1 is a diagrammatic representation showing the halves of a stainless steel flow-through diffusion cell.
    • Fig. 2 is a graphical representation showing the effect of pretreatment with various enhancers on the diffusion of ketoprofen across shed snake skin.
    • Fig. 3 is a graphical representation showing the effect of various enhancers on the diffusion of ketoprofen across shed snake skin.
    • Fig. 4 is a graphical representation showing the diffusion of ibuprofen from gel formulations across shed snake skin.
    • Fig. 5 is a graphical representation showing the plasma profile of testosterone in domestic weanling pigs after a single application of a metered dose topical aerosol. Error bars represent standard error of the mean.
    • Fig. 6 is a graphical representation showing the plasma profile of estradiol in domestic weanling pigs after a single application of a metered dose topical aerosol. Error bars represent standard error of the mean.
    • Fig. 7 is a graphical representation showing the plasma profile of testosterone in castrated domestic weanling pigs after the sixth once daily application of a metered dose topical 5 aerosol. Each point represents the mean of 4 individual values and the error bars represent standard error of the mean. Testosterone levels shown are baseline subtracted and the mean baseline (±sem) on Day 1 at 0 h was 0.8 ng.ml-1 ± 0.3 ng.ml-1.
    • Fig. 8 is a graphical representation showing the predicted testosterone input across human skin in vivo and children's python snake skin in vitro. Error bars represent standard error of the mean.
    • Fig. 9 is a graphical representation showing the predicted testosterone plasma concentration in hypogonadal males after once daily dosing to steady-state with a metered dose topical spray.
  • In the examples, the effectiveness of the penetration enhancers are illustrated by measuring the skin penetration of formulations of a number of representative physiologically active agents with the dermal penetration enhancers. Also, the skin penetration of physiologically active agents was measured with other prior art penetration enhancers as well as formulations of the physiologically active agents with common adjuvants, which serve as control formulations. The comparisons made generally consisted of measuring the relative penetration through shed snake skin of the various formulations. In every case, those formulations which contained the dermal penetration enhancers delivered more of the active agent through the skin than did the corresponding control formulation or commercial preparation.
  • In Vitro Skin Diffusion Measurements Shed Snake Skin
  • The Children's python shed snake skin was obtained during natural shedding and the dorsal skin was used. Shed snake skin has shown to be a suitable model membrane for human skin by Itoh, et al., Use of Shed Snake Skin as a Model Membrane for In Vitro Percutaneous Penetration Studies: Comparison with Human Skin, Pharm. Res., 7(10), 1042-1047, 1990; and Rigg, et al., Shed Snake Skin and Hairless Mouse Skin as Model Membranes for Human Skin During Permeation Studies, J. Invest. Dermatol., 94; 235-240,1990.
  • Full Thickness Skin
  • The animals used in these investigations were obtained from the animal house at the Victorian College of Pharmacy, Monash University, Parkville, Australia.
  • a. Hairless Mouse Skin
  • Hairless mice of 4-8 weeks of age were used. The mouse skin was excised and full-thickness skin was isolated from the torso, the subcutaneous fat and connective tissue removed and the skin cut into circles of 2-0 cm2, then placed into the diffusion cells for flux measurements.
  • b. Guinea Pig Skin.
  • Adult guinea pigs of either sex (weight range 500g - 750g) were used. The hair on the back flank and back was removed with the aid of depilatory wax (Arielle™) under halothane anaesthesia. Seven days later, after the stratum corneum had completely regenerated, the guinea pigs were killed and the skin removed and placed on a chilled slab. The subcutaneous fat and connective tissue removed and the skin cut into circles and then placed into the diffusion cells for flux measurements. For in vivo experiments the guinea pigs were housed in individual cages and the topical hydroquinone formulations were applied to the hair-free areas. Each guinea pig received the test or control formulation on the corresponding contralateral site, thus allowing each animal to act as its own control.
  • In Vitro Skin Diffusion Experiments in Franz-type Cells
  • The work using Hydroquinone was performed using vertical Franz diffusion cells which had an effective diffusional area of 1.3 cm2, a receiver chamber temperature of 37 or 32 degrees Celsius and receiver chamber volume of 13 mL of normal saline.
  • In Vitro Skin Diffusion Experiments in Horizontal Diffusion Cells
  • A modified stainless steel flow-through diffusion cell assembly based on that first shown by Cooper in J.Pharm.Sci. 73(8), 1984, was used to perform the experiments on diffusion of the drugs from various donor compositions through the skin (either snake or hairless mouse). The flow-through diffusion cell used to perform the present experiments is shown in Figure 1. The cell consists of an upper section (1) and a lower section (2). A stainless steel wire mesh support (4) is housed in a recess (5) in the lower section of the cell. The skin sample (3), cut into a circle, is gently placed over the support (4) and the two sections (1,2) of the cells are secured together by screws (not shown), using the locating holes (9), to form a tight seal. An aperture (8) in the upper section of the cell, which has an area of 0.79 cm2 (0.5 cm in diameter) forms a well above the skin into which the topical formulation is applied. In most cases 400 microL of formulation, solution or suspension containing the drug substance to be tested was applied evenly over the skin. The bottom section of the cell is provided with inlet (6) and outlet (7) tubes which connect to the bottom of the recess (5) and through which a receptor solution was pumped by a microcassette peristaltic pump (Watson Marlow, UK) (not shown) at a constant flow rate to maintain sink conditions. The receptor solution consisted of 50% propylene glycol in water, made isotonic with 0.9% sodium chloride and preserved with 0.1% sodium azide or 0.1% sodium fluoride. To prevent air bubbles forming under the skin, the wire mesh (4) ensures turbulent receptor flow. The recess (5) is filled with receptor solution prior to placing the skin in the cell. The receptor solution was degassed by spraying the solution into fine droplets under vacuum while stirring at 40°C. Degassing was repeated three times. These precautions eliminated the need for a bubble chamber in the diffusion cell. The diffusion cells were set on a hollow metal heater bar which maintained normal skin temperature of 32°C (±0.5 °C) means of heated, circulating water (Thermomix, Braun, Germany). Each diffusion cell had its receptor solution collected via tube (7) into polyethylene vials (6 ml liquid scintillation vials, Packard instruments, Netherlands) at two or four hour intervals for 24 hours, by means of an automated rotating fraction collector (Retriever II, ISCO, Australia). The amount of drug in each vial containing receptor solution was determined by reverse phase HPLC. Prior to analysis each vial was weighed with an analytical balance (Mettler AT261, Australia) and the volume calculated from the density of the receptor solution which was 1·0554 g/cm3 at 22°C.
  • The concentration of applied drug in each diffusion cell sample was measured using high pressure liquid chromatography (HPLC). The receptor solution was assayed neat, with 20 microL injected (WISP 712 autoinjector, Waters, Australia) into a freshly prepared and degassed (by filtering) mobile phase. Each drug was separated using a pre column fitted with a C18 insert and a µBandapak C18 (30 cm x 3.9 nm) HPLC column (Waters). Absorbance was measured at the appropriate wavelength using a Waters tuneable absorbance detector and peak area was plotted and integrated using a Shimadzu C-R3A chromatopac integrator. The results reported for each experiment are the average, values of four replicate diffusion cells unless stated otherwise. The assay conditions used for each different drug are given in each example.
  • EXAMPLE 1
  • The in vitro diffusion cell method described above was used to compare the penetration of 400 microL of 2 % w/v ketoprofen in 70 % v/v aqueous ethanol applied to the shed snake skin following the application of 400 microL of the different dermal penetration enhancers in a 2 % v/v solution in 70 % ethanol, 2 hours prior to the application of the ketoprofen. The control experiment involved application of 400 microL of 70 % aqueous ethanol alone for 2 hours, followed by application of 400 microL of the 2 % ketoprofen solution. Samples were assayed according to the method described previously. The detection wavelength was 255 nm and the mobile phase consisted of acetonitrile:water (55:45) made to pH 3.0 with orthophosphoric acid (BDH, Australia). Table 1 shows the mean flux of ketoprofen across the snake skin over 24 hours as determined by the linear regression of the cumulative amount of ketoprofen crossing the skin versus time (Units = microg/cm2.h). Figure 2 shows the representative mean cumulative amount versus time plots for ketoprofen. TABLE 1
    Enhancer type Mean flux +/- std error (microg/cm2.h) p value relative to control Enhancement ratio
    Control - no enhancer, n = 9 0.96 ± 0.18 - -
    Azone, n = 2 2.58 ± 0.23 0.0029 2.7
    Octyl dimethyl PABA, n = 3 2.25 ± 0.14 0.0068 2.3
    Octylmethoxy cinnamate, n = 3 3.22 ± 0.28 0.0003 3.35
    Octyl salicylate, n = 2 27.66 ± 5.26 <0.0070 28.81
    NB. Enhancement ratio = mean flux enhancer / mean flux control
  • Statistical significance was determined by means of a Student's t-test. Azone was selected as the standard penetration enhancer for comparison since it has been widely used in previous percutaneous penetration experiments.
  • EXAMPLE 2
  • The in vitro diffusion cell method described above was used to compare the penetration of 30 microL of the commercial formulation Indospray™ (Rhone-Poulenc Rorer, Australia), which is a 1.0 % w/w solution of indomethacin in 95 % v/v ethanol when applied to the snake skin. 10 microL of increasing concentrations of Octyl dimethyl PABA in absolute ethanol were applied 30 mins prior to the application of the indomethacin formulation. The control experiment involved application of 10 microL of absolute ethanol alone 30 mins prior to the application of the indomethacin formulation. Samples were assayed according to the method described previously. The detection wavelength was 254 nm and the mobile phase consisted of acetonitrile:water (55 % v/v : 45 % v/v) made to pH 3·0 with orthophosphoric acid. Table 2 shows the mean flux of indomethacin across the snake skin over 24 hours. TABLE 2
    Enhancer type Enhancer conc. (%v/v) Mean flux +/- std error (microg.cm2.h) p value relative to control Enhancement ratio
    Control - no enhancer n/a 1.24 +/- 0.05 - -
    Octyl dimethyl PABA 1.6 1.43 +/- 0.14 ns 1.2
    as above, n = 3 3.2 1.71 +/- 0.32 ns 1.4
    as above 6.4 1.94 +/- 0.09 0.0005 1.6
    ns = not statistically significantly different
  • These results demonstrate the ability of the dermal penetration enhancers to be applied alone prior to exposure of the skin to the physiologically active ingredient(s) formulations without penetration enhancers. Enhancement of percutaneous absorption is extensive, as well as being dose-dependent in manner, such that the desired level of enhancement can be achieved by utilising the appropriate dose of dermal penetration enhancer applied to the skin.
  • EXAMPLE 3
  • The same protocol as Example 1 was repeated, except the dermal penetration enhancers were included in the ketoprofen formulation, such that 400 microL of 2 % w/v ketoprofen and 2 % v/v dermal penetration enhancer in 70 % v/v aqueous ethanol was applied to the skin from the start of the diffusion experiment.
  • Table 3 shows the mean flux of ketoprofen across the snake skin over 24 hours. Figure 3 shows the representative mean cumulative amount versus time plots for ketoprofen. TABLE 3
    Enhancer type Mean flux +/- std error (microg/cm2.h) p value relative to control Enhancement ratio
    Control - no enhancer, n = 10 0.78 ± 0.07 - -
    Azone, n = 2 2.84 ±0.11 <0.0001 3.6
    Octyl dimethyl PABA, n = 2 2.71 ± 0.18 <0.0001 3.5
    Octylmethoxy cinnamate, n = 2 2.08 ± 0.39 0.0413 2.7
    Octyl salicylate, n = 4 61.68 ± 14.89 <0.0059 79.1
  • These results demonstrate the ability of the dermal penetration enhancers to be applied together with the physiologically active ingredient/s within the same formulation to achieve their percutaneous absorption enhancement.
  • Reference EXAMPLE 4
  • Table 4 shows the mean flux (% dose/h) +/- the standard error of the mean of hydroquinone (HQ) penetrated across full-thickness guinea pig skin in vitro from a gel formulation applied to the skin at a dose of 15 mg/cm2. Radiolabelled hydroquinone (C14, Amersham) was added to each of the topical formulations. At specified time intervals 200 microL of receptor solution was withdrawn with a micro-pipette and replaced with 200 microL of fresh normal saline. The 200 microL samples were added to 800 microL of water which in turn was added to 10 mL of scintillation cocktail consisting of Toluene™ 1L, PPO 5g, POPOP 0.1g and Triton X™ 500 mL. The scintillation counting was performed on a Packard Tricarb 460C instrument. Disintegrations per minute were determined by an external standard procedure and calculated by the data system of the instrument. TABLE 4
    Enhancer type Flux (%dose/h) Enhancement ratio (enhancer/ control)
    PARSOL® MCX 3% v/v 0.93 ± 0.19* 2.7
    ESCALOL® 507 3% v/v 1.02 ± 0.09* 2.9
    AZONE 5% v/v, PARSOL® MCX 3% v/v 1.48 ± 0.08* 4.3
    AZONE 5% v/v, ESCALOL® 507 3% v/v 0.74 ± 0.02* 2.1
    PARSOL® MCX 3% v/v, ESCALOL® 507 3% v/v 1.30 ± 0.10* 3.7
    Control (no enhancer) 0.35 ± 0.10 -
    n > or =10, * statistically significantly different from control, p < 0:01 following student t-test:
  • Table 5 shows the effect of hydroquinone (HQ) penetration across full-thickness guinea pig skin in vivo on the mean melanin content (mg/cm2) +/- standard error of the mean following the application of a finite dose solution (5 microL/cm2). Melanin content was measured by reflectance absorbance from the treated and untreated skin according to the methods outlined in the PhD thesis of Anderson, J.R., titled The Development of Techniques for Measuring the Bioavailability of Topical Depigmenting Agents (School of Pharmaceutics, Victorian College of Pharmacy Ltd., Parkville, Victoria, Australia, Dec., 1985). TABLE 5
    HQ concentration / Enhancer type Melanin content (µg/cm2) p value relative to control Enhancement ratio (enhancer/ control)
    HQ 1% w/v control* 57.5 ± 3.7 -
    HQ 1% w/v, Octyl dimethyl PABA 2% v/v 38.2 ± 3.1 0.002* 1.5
    HQ 2% w/v control^ 36.8 ± 8.1 -
    HQ 2% w/v, Azone 2% v/v 39.5 ± 9.6 0.35^ 0.93
    n = 8, Statistically significant differences tested for using a Student t-test.
  • EXAMPLE 5
  • Table 6 shows the median amount (µg/cm2) of ibuprofen penetrated across full-thickness hairless mouse skin in vitro when 400 microL of a 2 % w/v ibuprofen and 2 % v/v dermal penetration enhancer in 70 % v/v aqueous ethanol is applied. Again Azone was selected as the standard for comparison and the control formulation contained no penetration enhancer. The detection wavelength was 210 nm and the mobile phase consisted of acetonitrile:water (55:45) made to pH 3-0 with orthophosphoric acid. TABLE 6
    Enhancer type after 12 hours after 24 hours
    Octyl methoxycinnamate 2% v/v 1099* 2458*
    Octyl dimethyl PABA 2% v/v 1123* 2981*
    Azone 2% v/v 1036* 2684*
    Control (no enhancer) 474 1819
    n = 8, * statistically significantly different from control, p < 0.05 following ANOVA on Ranks.
  • EXAMPLE 6
  • Table 7 shows the mean amount (µg/cm2) +/- standard error of the mean of testosterone penetrated across dermatomed (300 µm thickness) neonate porcine skin in vitro when 10 microL of a 12 % w/v testosterone and 8 % v/v of dermal penetration enhancer in absolute ethanol was applied. The detection wavelength was 241 nm and the mobile phase consisted of acetonitrile:water (55% :45%). TABLE 7
    Enhancer type after 4 hours after 24 hours
    Octyl dimethyl PABA 8% v/v 72 ± 10* 227 ± 7*
    Control (no enhancer) 4 ± 1 13 ± 2*
    Enhancement ratio 18 17
    n = 3, * statistically significantly different from control, p < 0.003 following Student t-test.
  • EXAMPLE 7
  • Figure 4 shows the cumulative amount of ibuprofen transferred across shed snake skin versus time for gel formulations of ibuprofen. 5 mg of each gel was applied to the skin. Samples were assayed by the HPLC method mentioned in Example 5. The gels were made to a final concentration of 5 % w/w ibuprofen and 2 % w/w dermal penetration enhancer by first dissolving them in 50 % v/v aqueous ethanol then adding 2 % w/w Sepigel 305™ (SEPPIC, Paris, France) as a gelling agent and stirring at room temperature until a gel was formed. This formulation was compared with the commercial IBUGEL™ (Dermal Laboratories, UK) formulation which contained 5 % w/w ibuprofen in a ethanolic gel base formed with carbopol. As well, 2 % w/w dermal penetration enhancer was added to the IBUGEL by simple mixing. The ibuprofen contents of each gel were determined by HPLC and were found to be 5.02, 5.75 and 5.43 mg/g for the gel using Sepigel-305™ and enhancer, the IBUGEL and the IBUGEL with enhancer, respectively.
  • Both the cumulative amounts at 12 an 24 h and the mean flux over 24 h were significantly greater (p < 0.05) for both the enhanced gel formulations when compared to the commercial IBUGEL formulation. The flux enhancement ratios were 6.15 and 2.61 for the gel using Sepigel-305™ and enhancer and the IBUGEL with enhancer (n = 3) respectively when compared to the IBUGEL (p < 0.05).
  • Reference EXAMPLE 8
  • Table 8 shows the mean flux (g/cm2 .h) of hydrocortisone penetrated across snake skin in vitro when 400 microL of 1 % w/v hydrocortisone and 2 % v/v octyl dimethyl PABA in 70% v/v aqueous ethanol was applied. The control formulation contained no penetration enhancer. The detection wavelength was 242 nm and the mobile phase consisted of acetonitrile:water (35% :65%). TABLE 8
    Enhancer type Mean flux +/- std error (microg/cm2.h) p value relative to control Enhancement ratio
    Control- no enhancer 0.14 +/- 0.04 - -
    Octyl dimethyl PABA 8% v/v 0.79 +/- 0.06 < 0.0001 5.8
  • EXAMPLE 9
  • Table 9 shows the mean flux over 24 h of ketoprofen from a transdermal patch using the enhancer octyl salicylate compared with a control without enhancer. The patches were prepared by dissolving 300 mg of ketoprofen, 400 mg of penetration enhancer, 300 mg of polyethylene glycol 400 and 800 mg of hydroxypropylcellulose in 20 mL of ethanol and stirring until viscous. This was then poured onto a clean glass plate and dried at 40 degrees Celsius for 1 h. The thickness of this film was approximately 1 mm. Circles of 0.8 cm2 were then cut out of this matrix and stuck onto the middle of 2.0 cm2 circles of OPSITE™ adhesive bandage. This patch was then stuck onto 2.0 cm2 pieces of snake skin and placed in the diffusion cell. The ketoprofen content of each patch formulation was determined by HPLC in triplicate and found to be 6.99 +/- 0.30 mg/cm2 and 6.76 +/-0.24 mg/cm2, for the control and octyl salicylate patches respectively (mean content +/std error, n=4). TABLE 9
    Enhancer type Mean flux +/- std error (microg/cm2.h) p value relative to control Enhancement ratio
    Control - no enhancer 0.47 ± 0.04 - -
    Octyl salicylate 11.70 ± 0.65 <0.0001 25.2
  • In order to further illustrate the present invention and the advantages thereof, the following specific examples are given, it being understood that same are intended only as illustrative and in nowise limitative. In the examples, the effectiveness of the dermal penetration enhancers are illustrated by measuring the skin penetration of physiologically active agents. Also, the skin penetration of the dermal penetration enhancers of this invention were compared with that of other penetration enhancers as well as formulations of bio-affecting agents with common adjuvants. The comparisons made generally consisted of measuring the relative penetration through shed snake skin of the various formulations. In the examples, the in vitro skin penetration studies were performed using the same in vitro diffusion cell apparatus as previously mentioned.
  • EXAMPLE 10
  • Figure 5 shows the mean cumulative amount of testosterone which crosses the shed snake skin versus time.
  • The volume of each formulation applied to the skin was 5 microL/cm2. Each formulation contained 12 % w/v testosterone in absolute ethanol. The dose was applied with a GC syringe. All except for the control formulation had a penetration enhancer added at a concentration of 8 % v/v.
  • Samples were assayed for testosterone by HPLC as shown before in Example 6.
  • Table 10 shows the mean flux of testosterone over 24 h for each of the formulations and the degree of enhancement expressed as the ratio of the mean flux of the penetration enhancer formulation divided by the mean flux of the control formulation. TABLE 10
    Enhancer type Mean flux +/- std error (microg/cm2.h) p value relative to control Enhancement ratio
    Control - no enhancer 0.70 +/- 0.03 - -
    Oleic acid 2.09 +/- 0.08 < 0.0001 3.0
    Azone 2.02 +/- 0.27 < 0.03 2.9
    Octyl dimethyl PABA 1.43 +/- 0.25 < 0.03 2.0
    Octyl salicylate 4.18 +/- 0.41 < 0.03 6.0
  • EXAMPLE 11
  • Table 11 shows the mean flux over 24 h and the enhancement ratios for a number of different preferred compounds after they are applied to the skin at a dose of 5 microL/cm2. The two penetration enhancers given as examples are octyl dimethyl PABA and Azone. Both penetration enhancers were again at a concentration of 8 % v/v within the formulations and control was without a penetration enhancer. A concentration of 2 % w/v oestradiol was used in the formulation and detection wavelength was 212 nm and the mobile phase consisted of acetonitrile:water (40%:60%). A concentration of 6 % w/v progesterone was used in the formulation, the detection wavelength was 240 nm and the mobile phase consisted of acetonitrile:water (55%:45%). A concentration of 6 % w/v norethisterone acetate was used in the formulation, the detection wavelength was 240 nm and the mobile phase consisted of acetonitrile:water (55 % :45 %) adjusted to pH 3.0 with orthophosphoric acid. A concentration of 20 % ibuprofen was used in the formulation, the detection wavelength was 210 nm and the mobile phase consisted of acetonitrile:water (55%:45%) adjusted to pH 3.0 with orthophosphoric acid. A concentration of 20 % flurbiprofen was used in the formulation, the detection wavelength was 247 nm and the mobile phase consisted of acetonitrile:water (55 % :45 %) adjusted to pH 3.0 with orthophosphoric acid. TABLE 11
    Drug Enhancer type Mean flux +/- std error (microg/cm2.h) p value cf. control Enhancement ratio
    Oestradiol Control, n = 3 0.06 +/- 0.01 - -
    Azone 0.40 +/- 0.05 < 0.003 6.4
    Octyl dimethyl PABA 0.26 +/- 0.01 < 0.0001 4.1
    Progesterone Control, n = 3 0.40 +/- 0.02 - -
    Azone; n = 3 2.17 +/- 0.33 < 0.05 5.4
    Octyl dimethyl PABA 0.95 +/- 0.03 < 0.0001 2.4
    Norethisterone acetate Control 0.14 +/- 0.02 - -
    Azone 0.16 +/- 0.02 < 0.0001 1.1
    Octyl dimethyl PABA 1.85 +/- 0.07 < 0.0001 12.8
    Ibuprofen Control 5.39 +/- 0.50 - -
    Azone 13.53 +/- 1.38 0.0014 2.5
    Octyl dimethyl PABA 13.16 +/- 1.21 0.001 2.4
    Flurbiprofen Control, n = 3 0.81 +/- 0.05 - -
    Azone 2.05 +/- 0.42 0.0559 2.5
    Octyl dimethyl PABA, n = 3 2.91 +/- 0.30 0.0023 3.6
  • The flux values obtained for these drugs are clinically relevant, given for example that in hormone replacement therapy for postmenopausal women the current transdermal delivery systems aim to provide 25 to 100 microg of estradiol per day and 250 microg of norethisterone per day (Estracombi™) and in testosterone replacement therapies the goal ranges from replacing 0.1 to 0.3 mg per day in women lacking testosterone (US patent No. 5,460,820), to 5 to 6 mg per day in testosterone deficient hypogonadal men (Androderm™) and up to 6 to 10 mg per day for male contraception (ref. J.Clin.Endocrinol.Metab., Vol. 81, 4113-4121, 1996). For the NSAIDs, ibuprofen and flurbiprofen increased drug flux is desirably predicated on the basis that this will lead to higher local concentrations of the active drug at the target site of pain and inflammation.
  • EXAMPLE 12
  • Figures 5 and 6 show the mean plasma levels of testosterone and oestradiol respectively following application of the topical transdermal aerosols (described previously in examples 15 and 14 respectively) to domestic weanling pigs (7 to 8 weeks old) in vivo. Plasma testosterone and oestradiol levels were determined by high specificity radioimmunoassays, using commercially available assay kits. The oestradiol assay (Orion Diagnostica, Finland) was conducted according to the manufacturers' directions. The testosterone assay (Pantex, CAL, USA) was also conducted according to the directions, with the procedure modified to include an extraction step (90% diethylether/10% ethyl acetate) to remove any species specific matrix effects. The control formulations were the same aerosol systems as above, except they did not contain any dermal penetration enhancer.
  • The male pigs receiving the testosterone dose were surgically castrated 1 week prior to the commencement of the study to remove any interference from endogenous testosterone production and at the same time a cephalic cannula was inserted to facilitate blood sampling. These procedures were performed under general anaesthetic halothane (Fluothane™).
  • The results shown are baseline subtracted, were the baseline testosterone level at time zero was 4.3 nmol/L +/- 1.1 nmol/L (mean +/- std error mean) for the test group (n = 4) and was < 0.5 nmol/L for every pig in the control group (n = 7). A single application of 9 sprays over 180 cm2 was applied at 9 am and blood samples were taken at the intervals shown over 24 h. The mean body weight of the pigs were 19.9 kg +/- 0.8 kg and 17.2 kg +/- 0.4 kg for the test and control groups respectively. The area under the plasma concentration versus time curve (AUC) was 2.2 fold greater (p < 0.05) for the penetration enhancer formulation compared with control. The calculated results for AUC were normalised to a body weight of 20 kg assuming volume of distribution is directly proportional to body weight.
  • The male pigs receiving the oestradiol dose had baseline oestradiol levels of < 0.02 nmol/L for every pig in the test group (n = 4) and < 0.02 nmol/L for every pig in the control group (n = 6). A single application of 3 sprays over 30 cm2 was applied at 9 am and blood samples were taken at the intervals shown over 24 h. The mean body weights of the pigs were 21.3 kg +/- 1.0 kg and 17.5 kg +/- 0.4 kg for the test and control group respectively. The area under the plasma versus time curve (AUC) was 14.1 fold greater (p < 0.0003) for the penetration enhancer formulation compared with control. The calculated results for AUC were normalised to a body weight of 20 kg assuming volume of distribution is directly proportional to body weight.
  • EXAMPLE 13
  • Male pigs were used as described above, and the testosterone spray was applied daily over 180 cm2 as described previously. Once daily testosterone application was performed at 9 am for 6 consecutive days, and on the sixth day blood samples were taken at the intervals shown over 24 h in Figure 7. A baseline blood sample was taken at time = 0 h, on day 1 and was 2.8 nmol/L +/-1.1 nmol/L (mean +/- std error mean), n = 4. Figure 7 shows the mean plasma level of testosterone versus time over 24 h. The results shown are baseline testosterone subtracted and are representative of the expected steady-state profile for testosterone.
  • Figure 8 shows the mean cumulative amount of testosterone crossing the domestic weanling pig skin in vivo, as determined by Wagner-Nelson analysis, which says that Flux = Plasma conc. x Clearance (Berner B., John V.A., Pharmacokinetic Characterisation of Transdermal Delivery Systems, Clin. Pharmacokinet., 26(2): 121-134, 1994.). Clearance was determined prior to study commencement by a bolus dose of intravenous testosterone and was found to be 663 ml/h.kg +/- 139 ml/h.kg which was similar to the reported value for males of 655 ml/h.kg (Mazer N.A. , Heiber W.E. , Moellmer J.F. , Meikle A.W., Stringham J.D., Sanders S.W., Tolman K.G., Odell W.D., Enhanced transdermal delivery of testosterone: a new physiological approach for androgen replacement in hypogonadal men, J. Control. Releas., 19, 347-362, 1992). Also included for comparison in Figure 8 are the expected in vivo penetration across human skin and the in vitro penetration of testosterone across shed snake skin. The in vivo penetration across human skin was based on a 2.2 fold lower permeability of testosterone in human skin compared with pig skin as determined in vivo (Bartek M.J., LaBudde J., Maibach H.I., Skin Permeability In Vivo: Comparison in Rat, Rabbit, Pig and Man, J. Invest. Dermatol., 58(3): 114-123, 1972);
  • Figure 8 shows the controlled nature of testosterone penetration across the skin in vivo, as well as the good predictive capability of the in vitro shed snake skin diffusion model for ascertaining the likely penetration of the testosterone across human skin. It is therefore envisaged that the flux values obtained in examples 10 and 11 will be very similar to those obtained in humans in a clinical setting.
  • Further to this Figure 9 depicts the predicted plasma levels of testosterone in male subjects of a nominal weight of 70 kg based upon the clearance value of testosterone in males shown above. For comparison the 95 % confidence interval of the testosterone plasma level in normal healthy adult males is given (Mazer, et al.,J. Control. Releas., 19, 347-362, 1992). As shown this delivery system is quite capable of achieving the desired level of testosterone replacement in testosterone deficient hypogonadal men based upon on simple once daily application of the delivery system.
  • Aerosol Device
  • A plastic-coated glass aerosol container of 10 ml fill volume was fitted with a pharmaceutical grade metered-dose valve of a nominated discharge volume (50 µl for the oestradiol aerosol and 100 µl for the testosterone aerosol).
  • A stainless steel O-ring locks the valve in place on the aerosol container.
  • The aerosol container is charged with at least one physiologically active agent, non-volatile dermal penetration enhancer, volatile liquid carrier and optionally any other diluents, carriers, surfactants or additives followed by the propellant according to any suitable process.
  • A pharmaceutical grade spray nozzle and an aerosol shroud is fitted to keep the spray nozzle perpendicular to the skin at a height of 50 mm.
  • Method of Aerosol Use
  1. 1. Hold the device upright in the palm of your preferred hand with your thumb resting gently on the actuator button.
  2. 2. Rest the shroud opening on the skin and depress the actuator button once and release the button. Remove the device from the skin.
  3. 3. Repeat steps 1 and 2 on a new area of skin until the correct number of doses have been given.
  4. 4. Allow the applied formulation to dry on the skin for 1 minute.
  • During application of the spray, the nozzle shroud envelopes the spray, providing an effective closed system which deposits the active agent into the skin, and such that when the spray hits the surface of the skin it does not undergo any appreciable bounce-back into the atmosphere. A defined dose of active agent and penetration enhancer is forced through a uniform spray nozzle at a constant pressure form a defined height to give a uniform dose per cm2.
  • EXAMPLE 14
  • 17-β-Oestradiol Metered-Dose Transdermal Aerosol
    Active ingredient: Concentration
    17-β-Oestradiol 2 % w/v
    Non-volatile dermal penetration enhancer:
    Octyl dimethyl-para-aminobenzoate (Escalol 507, Padimate O) 8% v/v
    Volatile liquid:
    Absolute ethanol (AR) 60 % v/v
    Volatile propellant:
    Dimethyl ether 30 % v/v
    to give a final formulation pressure of 2.0 kp/cm2 (30 psi).
  • One spray of 50 µl will apply 1 mg of 17-β-oestradiol over an area of approximately 10 cm2. 3 sprays will be administered to the forearm skin, applying a dose of 3 mg over approximately 30 cm2.
  • EXAMPLE 15
  • Testosterone Metered-Dose Transdermal Aerosol
    Active ingredient: Concentration
    Testosterone 12% w/v
    Non-volatile dermal penetration enhancer:
    Octyl dimethyl-para-aminobenzoate (Escalol 507, Padimate O) 8% v/v
    Volatile liquid:
    Absolute ethanol (AR) 50% v/v
    Volatile propellant:
    Dimethyl ether 35% v/v
    to give a final formulation pressure of 2.4 kp/cm2 (35 psi).
  • One spray of 100 µl will apply 12 mg of testosterone over an area of approximately 20 cm2. 9 sprays will be administered to a defined area of skin on the torso (rib cage), applying a dose of 108 mg over approximately 180 cm2.
  • EXAMPLE 16
  • Analgesic mousse with penetration enhancement
    Ingredient: Concentration
    Ibuprofen 5% w/w
    2-ethylhexyl-p-methoxycinnamate 5% w/w
    nonionic emulsifier 2.5% w/w
    ethyl alcohol (95 %) 32.5% w/w
    purified water 50% w/w
    hydrocarbon propellant 5% w/w
  • Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.
  • Claims (9)

    1. Use of a non-occlusive, percutaneous or transdermal drug delivery system which comprises:
      (i) an effective amount of at least one physiologically active agent which is a drug, or prodrug thereof;
      (ii) at least one non-volatile dermal penetration enhancer; and
      (iii)at least one volatile liquid;
      wherein the dermal penetration enhancer is one or more of octyl dimehtyl-para-aminobenzoate, octyl para-methoxycinamate or octyl salicylate;
      in the manufacture of a medicament for the treatment or prophylaxis of soft tissue injury, narcotic withdrawal, severe post-operative pain, motion sickness, oestrogen dependent breast cancer, prostatic enlargement and/or prostatic cancer, anxiety disorders, male impotence, Raynauds syndrome, varicose veins, sleep disorders, herpes virus infections, deep vein thrombosis, migraine, high blood pressure, malaria, asthma, nocturnal asthma, psychotic disorders, severe post-natal depression or obesity, or for male hormone replacement in testosterone deficient hypogonadal men, female hormone replacement therapy for postmenopausal women, androgen replacement therapy for females lacking libido;
      wherein said treatment or prophylaxis comprises administering to a dermal surface or mucosal membrane of said animal in need of such treatment a therapeutically effective amount of the drug delivery system.
    2. Use according to claim 1, characterised in that the drug delivery system is not supersaturated with respect to the physiologically active agent or prodrug.
    3. Use according to claim 1 or claim 2, characterised in that the volatile liquid is ethanol or isopropanol.
    4. Use according to any one of claims 1 to 3, characterised in that the system is applied to the dermal surface or mucosal membrane by an aerosol, as a spray.
    5. Use according to claim 4, characterised in that the aerosol is a fixed or variable metered dose aerosol.
    6. Use according to any one of claims 1 to 5, wherein said system further comprises a pharmaceutical compounding agent, co-solvent, surfactant, emulsifier, antioxidant, preservative, stabiliser, diluent or a mixture of two or more of said components.
    7. Use according to any one of claims 1 to 6, characterised in that the physiologically active agent is a steroid, hormone derivative, non-steroidal anti-inflammatory drug, opioid analgesic, antinauseant, antioestrogen, aromatase inhibitor, 5- alpha reductase inhibitor, anxiolytic, prostaglandin, anti-viral drug, anti-migraine compound, anti-hypertensive agent, anti-malarial compound, bronchodilator, anti-depressant, anti-alzheimer's agent, neuroleptic and antipsychotic agent, anti-parkinson's agent, antiandrogen or anorectic agent.
    8. Use according to claim 7, characterised in that the physiologically active agent is testosterone, oestradiol, ethinyloestradiol, progesterone, norethisterone acetate, ibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, fentanyl, buprenorphine, scopolamine, prochlorperazine, metochlopramide, ondansetron, tamoxifen, epitiostanol, exemestane, 4-hydroxy-androstenedione and its derivatives, finasteride, turosteride, LY191704, alprazolam, alprostadil, prostacylcin and its derivatives, melatonin, n-docosanol, tromantadine, lipophilic pro-drugs of acyclovir, low molecular weight heparin, enoxaparin, sumatriptan, amlodipine, nitrendipine, primaquine, minoxidil, minoxidil prodrugs, pilocarpine, salbutamol, terbutaline, salmeterol, ibogaine, bupropian, rolipram, tacrine, fluphenazine, haloperidol, N-0923, cyproterone acetate or mazindol.
    9. Use according to any one of claims 1 to 8, characterised in that the animal is a human.
    EP97904304A 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same Expired - Lifetime EP0901368B1 (en)

    Priority Applications (3)

    Application Number Priority Date Filing Date Title
    AUPN8144A AUPN814496A0 (en) 1996-02-19 1996-02-19 Dermal penetration enhancer
    AUPN8144/96 1996-02-19
    PCT/AU1997/000091 WO1997029735A1 (en) 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same

    Applications Claiming Priority (4)

    Application Number Priority Date Filing Date Title
    EP06025287A EP1769785B1 (en) 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same
    EP05022951A EP1674068B1 (en) 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same
    LU91971C LU91971I2 (en) 1996-02-19 2012-04-04 fentanyl
    LU91972C LU91972I2 (en) 1996-02-19 2012-04-04 Fentanyl and applicator and metering

    Related Child Applications (1)

    Application Number Title Priority Date Filing Date
    EP05022951A Division EP1674068B1 (en) 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same

    Publications (3)

    Publication Number Publication Date
    EP0901368A1 EP0901368A1 (en) 1999-03-17
    EP0901368A4 EP0901368A4 (en) 2000-01-26
    EP0901368B1 true EP0901368B1 (en) 2006-05-03

    Family

    ID=3792458

    Family Applications (3)

    Application Number Title Priority Date Filing Date
    EP06025287A Expired - Lifetime EP1769785B1 (en) 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same
    EP05022951A Expired - Lifetime EP1674068B1 (en) 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same
    EP97904304A Expired - Lifetime EP0901368B1 (en) 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same

    Family Applications Before (2)

    Application Number Title Priority Date Filing Date
    EP06025287A Expired - Lifetime EP1769785B1 (en) 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same
    EP05022951A Expired - Lifetime EP1674068B1 (en) 1996-02-19 1997-02-19 Dermal penetration enhancers and drug delivery systems involving same

    Country Status (15)

    Country Link
    US (8) US6299900B1 (en)
    EP (3) EP1769785B1 (en)
    JP (2) JP4213211B2 (en)
    KR (1) KR100528602B1 (en)
    AT (3) AT472997T (en)
    AU (2) AUPN814496A0 (en)
    CA (1) CA2244089C (en)
    DE (7) DE69739931D1 (en)
    DK (3) DK0901368T3 (en)
    ES (3) ES2348313T3 (en)
    HK (3) HK1018884A1 (en)
    LU (3) LU91971I2 (en)
    NZ (1) NZ330942A (en)
    PT (3) PT901368E (en)
    WO (1) WO1997029735A1 (en)

    Families Citing this family (335)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US6861571B1 (en) * 1994-11-28 2005-03-01 The Procter & Gamble Company Article having a lotioned topsheet
    JPH10510540A (en) * 1994-12-12 1998-10-13 オメロス メディカル システムズ,インコーポレーテッド Irrigation solutions and pain, suppression method of inflammation and spasm
    US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
    US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
    US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
    US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
    US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
    AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
    US6916487B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
    US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
    US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
    GR1002847B (en) 1997-05-06 1998-01-27 Πετροσ Καρουζακησ Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection
    US6767902B2 (en) * 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
    US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
    US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
    US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
    US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
    US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
    US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
    US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
    EP1036561A1 (en) * 1997-10-01 2000-09-20 Flemington Pharmaceutical Corporation Buccal, non-polar spray
    US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
    US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
    US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
    US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
    US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
    US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
    US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
    US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
    US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
    US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
    US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
    US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
    US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
    US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
    US7098206B2 (en) 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
    US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
    US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
    US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
    WO1999038503A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmacological uses of optically pure (+)-bupropion
    WO1999038504A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
    CA2318738A1 (en) * 1998-01-29 1999-08-05 Paul D. Rubin Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
    DE19814084B4 (en) 1998-03-30 2005-12-22 Aderis Pharmaceuticals, Inc. (N.D.Ges.D. Staates Delaware) D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's disease and process for its preparation
    IL124764D0 (en) * 1998-06-04 1999-01-26 Univ Ben Gurion Topical composition for treatment of baldness
    DE19825591A1 (en) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmaceutical combinations to offset a testosterone deficit in men with prostate while protecting the
    GR1003199B (en) 1998-08-14 1999-09-01 Καρουζακησ Κωνσταντινου Πετροσ Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic threatment of problemes related to the female sexual malfunction
    AU768283B2 (en) 1998-08-20 2003-12-04 3M Innovative Properties Company Spray on bandage and drug delivery system
    CA2349487C (en) * 1998-12-08 2007-09-11 Planisphere Corp. Bupropion to treat viral diseases
    GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
    CA2370003C (en) 1999-01-13 2008-08-19 Tracey Brown A composition and method for the enhancement of the efficacy of drugs
    US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
    US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
    DE19918105C1 (en) 1999-04-22 2000-09-21 Lohmann Therapie Syst Lts Transdermal patch for administering neuroleptic agent i.e. fluphenazine, flupentixol or triflupromazine, includes matrix layer containing penetration enhancer and hydrocarbon polymer
    US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
    US6632419B2 (en) 1999-05-04 2003-10-14 Aradigm Corporation Increasing libido in humans via acute testosterone administration
    US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
    EP1175204A4 (en) * 1999-05-04 2006-05-31 Aradigm Corp Aerosol formulations and devices for increasing libido in women via acute testosterone administration
    US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
    US6312716B1 (en) * 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
    US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
    US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
    US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
    US6595947B1 (en) * 2000-05-22 2003-07-22 Becton, Dickinson And Company Topical delivery of vaccines
    US7241731B2 (en) 2000-06-05 2007-07-10 Sumitomo Electric Industries, Ltd. Oligopeptides for promoting hair growth
    US20050008602A1 (en) * 2000-06-05 2005-01-13 Sumitomo Electric Industries, Ltd. Oligopeptides for promoting hair growth
    AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
    US8388993B2 (en) * 2000-07-14 2013-03-05 Alchemia Oncology Pty Limited Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer
    US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
    US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
    AU8206401A (en) 2000-08-03 2002-02-18 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
    US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
    DE10041478A1 (en) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh New pharmaceutical composition
    DE10043321B4 (en) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and Lactationshemmung
    DE10041479A1 (en) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Novel pharmaceutical composition for the administration of N-0923
    DE10042411A1 (en) * 2000-08-30 2002-03-28 Lohmann Therapie Syst Lts A transdermal therapeutic system for the delivery of exemestane
    PL205279B1 (en) * 2000-08-30 2010-03-31 Unimed Pharmaceuticals, Inc. Method for treating erectile dysfunction and increasing libido in men
    US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
    US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
    WO2002020020A1 (en) * 2000-09-08 2002-03-14 Pharmacia Italia S.P.A. Exemestane as chemopreventing agent
    DE10053397A1 (en) 2000-10-20 2002-05-02 Schering Ag Use of a dopaminergic agent for the treatment of dopaminergic treatable diseases
    DE10064453A1 (en) * 2000-12-16 2002-07-04 Schering Ag Use of a dopaminergic agent for the treatment of dopaminergic treatable diseases
    US20020177626A1 (en) 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
    FR2815256A1 (en) * 2001-01-23 2002-04-19 Oreal Composition for cosmetic use comprises at least one derivative of sapogenin, preferably of hecogenin, and at least one solubilizing agent such as organic lipophilic UV filters
    JP3767392B2 (en) * 2001-02-05 2006-04-19 日産自動車株式会社 Camshaft of the engine rotational phase detection device and a cylinder intake air quantity calculating apparatus
    US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
    US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
    US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
    US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
    US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
    EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
    US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
    US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
    CA2451839C (en) * 2001-06-22 2013-08-06 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions comprising peptides and permeation enhancers
    US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
    WO2003018023A1 (en) * 2001-08-23 2003-03-06 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
    US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
    CA2458856C (en) * 2001-08-27 2011-02-15 Meditech Research Limited Improved therapeutic protocols
    US6723077B2 (en) 2001-09-28 2004-04-20 Hewlett-Packard Development Company, L.P. Cutaneous administration system
    CA2464994A1 (en) * 2001-10-29 2003-06-26 Becton, Dickinson And Company Method and device for the delivery of a substance
    US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
    US8226972B2 (en) 2001-12-20 2012-07-24 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
    US20040097871A1 (en) * 2002-01-03 2004-05-20 Israel Yerushalmy Apparatus for treating sleep disorders
    US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
    US20030161802A1 (en) * 2002-02-05 2003-08-28 Flammer Linda J. Anti-dandruff and anti-itch compositions containing sensate and sensate enhancer-containing compounds
    US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
    CA2489573A1 (en) * 2002-06-25 2003-12-31 Cosmeceutic Solutions Pty Ltd Topical cosmetic compositions
    US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
    US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
    AUPS317302A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Metastable pharmaceutical compositions
    AUPS317102A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
    NZ537360A (en) * 2002-06-25 2006-09-29 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
    AU2003238543B2 (en) * 2002-06-25 2008-02-28 Acrux Dds Pty Ltd Transdermal aerosol compositions
    US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
    DE10234673B4 (en) 2002-07-30 2007-08-16 Schwarz Pharma Ag Hot melt TTS for administering rotigotine and method for its production and use of rotigotine in the production of a TTS in a hot melt procedure
    EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
    US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
    US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
    US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
    US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
    US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
    US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
    US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
    US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
    US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
    IL152486D0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
    US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
    CA2502986C (en) 2002-10-25 2011-08-23 Foamix Ltd. Cosmetic and pharmaceutical foam
    US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
    US7192614B2 (en) 2002-11-05 2007-03-20 Gelstat Corporation Compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms
    US20040086579A1 (en) * 2002-11-05 2004-05-06 Higgins James W. Dietary supplement comprising parthenolide
    US7374772B2 (en) * 2002-11-07 2008-05-20 Bommarito Alexander A Topical antifungal treatment
    CA2507158A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Treatment of headache with antipsychotics delivered by inhalation
    DK1567164T3 (en) 2002-11-26 2009-05-18 Alexza Pharmaceuticals Inc Use of Loxapine for the manufacture of a medicament for the treatment of pain
    US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
    US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
    DK1426049T3 (en) * 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretic tilförsel of rotigotine for the treatment of Parkinson's disease
    US20040220198A1 (en) * 2002-12-20 2004-11-04 Kasturi Haldar Methods for treating malaria by modulation of G protein function
    US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
    CA2511995C (en) * 2003-01-02 2012-03-13 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
    US20040247707A1 (en) * 2003-01-06 2004-12-09 Le Roy Charles Richard Pearl blue fast acting, long lasting topical pain relief cream
    PL377933A1 (en) * 2003-01-23 2006-02-20 Shire Holdings Ag Formulation and methods for the treatment of thrombocythemia
    EP1444976A1 (en) * 2003-02-10 2004-08-11 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
    US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
    ITFI20030070A1 (en) * 2003-03-18 2004-09-19 Berlin Chemie Ag Topical stabilized formulations containing ketoprofen
    EA012599B1 (en) * 2003-04-10 2009-10-30 Ньюроджескс, Инк. Methods and compositions for administering agonists trpv1
    US7361376B2 (en) * 2003-04-11 2008-04-22 International Flavors & Fragrances Inc. Alkyldienamides exhibiting taste and sensory effect in flavor compositions
    US7632531B2 (en) * 2003-04-11 2009-12-15 International Flavors & Fragnances Inc. Alkyldienamides exhibiting taste and sensory effect in flavor compositions
    US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
    EP1625333A1 (en) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
    US20040247705A1 (en) * 2003-06-06 2004-12-09 Roberts Stephen C. Transdermal compositions and methods of treatment to alleviate or prevent migrainous headaches and their associated symptoms
    US20040247706A1 (en) * 2003-06-06 2004-12-09 Roberts Stephen C. Transdermal dietary supplement comprising parthenolide
    US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
    US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
    EP1488787A1 (en) * 2003-06-20 2004-12-22 Berlin-Chemie Ag Topical stabilized formulations containing ketoprofen
    CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
    US6884906B2 (en) * 2003-07-01 2005-04-26 International Flavors & Fragrances Inc. Menthyl half acid ester derivatives, processes for preparing same, and uses thereof for their cooling/refreshing effect in consumable materials
    US7141686B2 (en) 2003-07-10 2006-11-28 International Flavors & Fragrances Inc. E2, E4, Z8-undecatrienoic acid and ester and carboxamide derivatives thereof, organoleptic uses thereof and processes for preparing same
    US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
    US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
    US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
    DE10334188B4 (en) 2003-07-26 2007-07-05 Schwarz Pharma Ag Use of rotigotine to treat depression
    US7323191B2 (en) 2003-07-28 2008-01-29 Alza Corporation Transdermal warfarin system
    US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
    US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
    US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
    US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
    US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
    US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
    US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
    EP1660056A4 (en) * 2003-08-15 2008-12-17 Arius Two Inc Adhesive bioerodible transmucosal drug delivery system
    US20060018852A1 (en) 2003-08-22 2006-01-26 L'oreal Compositions containing topical active agents and pentylene glycol
    US20050043283A1 (en) * 2003-08-22 2005-02-24 L'oreal S.A. Compositions containing topical active agents and pentylene glycol
    US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
    US7329767B2 (en) * 2003-10-03 2008-02-12 International Flavors & Fragrances Inc. Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof
    US8007839B2 (en) * 2003-10-03 2011-08-30 International Flavors & Fragrances Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof
    US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
    BRPI0414551A (en) 2003-10-10 2006-10-31 Antares Pharma Ipl Ag transdermal or transmucosal pharmaceutical formulation and method of delaying or inhibiting crystallization of an active agent
    KR100552650B1 (en) * 2003-11-17 2006-02-20 아이큐어 주식회사 Antiphlogistic and analgesic plaster comprising Piroxicam compound
    US20050129756A1 (en) * 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
    EP1541136A1 (en) * 2003-12-10 2005-06-15 Schering AG UV light-stable semi-solid transdermal systems comprising a photosensitive active agent and an UV-absorbing component
    JP2007520262A (en) * 2003-12-10 2007-07-26 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッドAcrux Dds Pty Ltd The method of treating side effects associated with transdermal or topical drug delivery
    EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
    DE10361258A1 (en) 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of substituted 2-aminotetralines for the preventive treatment of Parkinson's disease
    DE102004014841B4 (en) 2004-03-24 2006-07-06 Schwarz Pharma Ag Use of rotigotine in the treatment and prevention of Parkinson's plus syndrome
    US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
    US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
    US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
    US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
    US8741332B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
    CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
    US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
    US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
    US20070264319A1 (en) * 2004-09-01 2007-11-15 Lebo David B Transdermal Antiemesis Delivery System, Method and Composition Therefor
    US7541055B2 (en) * 2004-09-10 2009-06-02 International Flavors & Fragrances Inc. Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions
    US7427421B2 (en) * 2004-09-10 2008-09-23 International Flavors & Fragrances Inc. Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions
    US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
    PT1814531E (en) 2004-10-21 2010-09-14 Durect Corp Transdermal delivery systems
    US7037513B1 (en) 2005-01-31 2006-05-02 Aquea Scientific Corporation Bodywash additives
    US7025952B1 (en) 2005-01-31 2006-04-11 Aquea Scientific Corporation Methods of preparation and use of bodywashes containing additives
    US20060173709A1 (en) * 2005-01-31 2006-08-03 Traynor Daniel H Bodywash additive business methods
    US6998113B1 (en) 2005-01-31 2006-02-14 Aquea Scientific Corporation Bodywashes containing additives
    US7001592B1 (en) * 2005-01-31 2006-02-21 Aquea Scientific Corporation Sunscreen compositions and methods of use
    US20080112904A1 (en) * 2005-03-08 2008-05-15 Daniel Henry Traynor Sunscreen Compositions And Methods Of Use
    WO2006084312A1 (en) * 2005-02-09 2006-08-17 Acrux Dds Pty Ltd Method of promoting hair growth
    CA2597651A1 (en) * 2005-02-14 2006-08-24 Neurogesx, Inc. Device for delivery of trpv1 agonists
    EP2767163A1 (en) 2005-02-17 2014-08-20 Abbott Laboratories Transmucosal administration of drug compositions for treating and preventing disorders in animals
    WO2006102267A2 (en) * 2005-03-21 2006-09-28 The Trustees Of Columbia University In The City Of New York New neuronal pain pathway
    ES2632631T3 (en) * 2005-03-24 2017-09-14 Ensign Laboratories Pty Ltd Aerosol spray and sunscreen
    AU2006227561B2 (en) * 2005-03-24 2011-06-09 Ensign Laboratories Pty Ltd Sunscreen aerosol spray
    US20060222690A1 (en) * 2005-03-30 2006-10-05 Bley Keith R Low-concentration capsaicin patch and methods for treating neuropathic pain
    US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
    CA2608344C (en) * 2005-05-16 2017-07-04 Steven Kritzler Method and composition for use in preparation of a patient for surgery
    WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
    KR20080033232A (en) 2005-06-03 2008-04-16 애크럭스 디디에스 피티와이 리미티드 Method and composition for transdermal drug delivery
    US8435944B2 (en) 2005-06-03 2013-05-07 Acrux Dds Pty Ltd. Method and composition for transdermal drug delivery
    US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
    KR100699582B1 (en) 2005-07-11 2007-03-23 삼성전기주식회사 Output buffer circuit
    US8937052B2 (en) * 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
    DK1909778T3 (en) * 2005-07-28 2018-03-19 Academisch Ziekenhuis Bij De Univ Van Amsterdam Monophenol, benzenediol or sulfhydryl compounds for use in the treatment of melanomas
    AU2006289651B2 (en) * 2005-09-07 2012-07-26 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
    SI2450041T1 (en) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Improved testosterone gel for use in the treatment of hypogonadism
    US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
    DE112006002834T5 (en) 2005-11-04 2008-10-30 Acrux DDS Pty. Ltd., West Melbourne Method and system for transdermal drug delivery
    PE06432007A1 (en) * 2005-11-21 2007-08-10 Schering Plough Ltd pharmaceutical compositions comprising buprenorphine
    EP1962795A1 (en) * 2005-12-07 2008-09-03 PharmaKodex Ltd Topical compositions for paediatric use
    GB0524961D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents for systemic effect
    GB0524958D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents
    GB0524962D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Topical pharmaceutical compositions
    JP2009524586A (en) * 2005-12-14 2009-07-02 ザーズ, インコーポレイテッド Compositions and methods for the pain skin treatment
    AU2006326388B2 (en) * 2005-12-14 2013-01-24 Nuvo Research Inc. Compositions and methods for treating dermatological conditions
    US9017717B2 (en) * 2006-01-16 2015-04-28 Peach Technologies Llc Bandage for facilitating transdermal respiration and healing
    MX2008009652A (en) 2006-01-24 2008-11-06 R Tech Ueno Ltd Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound.
    WO2007095586A2 (en) 2006-02-14 2007-08-23 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
    DE102006010329A1 (en) * 2006-03-06 2007-09-13 Höltge, Michael, Dipl.-Med. Hormonal contraceptive, comprises combination preparation of testosterone, gestogen, and esterogen, in the form of single, double or multi-phase preparation
    WO2007117581A2 (en) * 2006-04-06 2007-10-18 Collegium Pharmaceutical, Inc. Stabilized transdermal bupropion preparations
    WO2007123955A2 (en) * 2006-04-19 2007-11-01 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
    NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
    US9468600B2 (en) 2006-05-26 2016-10-18 Dr. Holmquist Healthcare, LLC Compositions for the transdermal delivery of physiologically active agents
    TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
    US20080090850A1 (en) * 2006-10-13 2008-04-17 Anderson Mark E Herpetic neuralgia topical treatment
    DE102006050558B4 (en) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing norelgestromin for contraception and hormone replacement therapy
    US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
    US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
    US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
    CA2673049C (en) * 2006-12-22 2016-02-23 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
    WO2008085984A1 (en) * 2007-01-08 2008-07-17 Androscience Corporation Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
    EP2106272A4 (en) 2007-01-11 2011-05-04 Acrux Dds Pty Ltd Spreading implement
    JP5319121B2 (en) 2007-01-30 2013-10-16 株式会社東芝 Medical support system and medical support device
    CA2682200C (en) 2007-03-19 2015-01-13 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
    WO2008128280A1 (en) * 2007-04-20 2008-10-30 Acrux Dds Pty Ltd Method and system for transdermal administration of volatile active
    BRPI0811430A2 (en) * 2007-05-10 2015-06-23 Novadel Pharma Inc anti-insomnia compositions and processes
    BRPI0811778A2 (en) * 2007-05-21 2014-09-30 Aquea Scient Corp highly loaded microcapsules
    DE102007032468A1 (en) 2007-07-10 2009-01-15 Brätter, Christian, Dr. Transdermal therapeutic systems, containing the active ingredient anastrozole
    HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
    US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
    AR068409A1 (en) * 2007-09-14 2009-11-18 Drugtech Corp pharmaceutical, transdermal compositions nonalcoholic
    AR068408A1 (en) * 2007-09-14 2009-11-18 Drugtech Corp Spraying transdermal hormone
    DK2214643T3 (en) * 2007-11-02 2014-05-26 Acrux Dds Pty Ltd A transdermal delivery system for hormones and steroids
    WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
    WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
    WO2009090558A2 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
    US20110052738A1 (en) * 2008-01-17 2011-03-03 Gary Dean Bennett Topical pain formulation
    US8123082B2 (en) * 2008-01-22 2012-02-28 McNeil-AB Hand-held dispensing device
    JP2011510059A (en) * 2008-01-25 2011-03-31 ビー アンド ティー エッセ.エッレ.エッレ. Use of transesterification olive oil in the cosmetics field
    JP4879928B2 (en) * 2008-03-25 2012-02-22 帝國製薬株式会社 Aqueous patch containing ketoprofen lysine salt
    US20090259176A1 (en) * 2008-04-09 2009-10-15 Los Gatos Research, Inc. Transdermal patch system
    EP2363116A1 (en) 2008-06-25 2011-09-07 US Worldmeds LLC Sustained-release formulations comprising lofexidine for oral delivery
    US20100048598A1 (en) * 2008-08-21 2010-02-25 Sateesh Kandavilli Topical compositions comprising 5-alpha reductase inhibitors
    AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
    US8748177B2 (en) * 2008-09-30 2014-06-10 The Hospital For Sick Children Compositions for proliferation of cells and related methods
    MX2011003510A (en) 2008-10-02 2011-06-17 Mylan Inc Method of making a multilayer adhesive laminate.
    WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
    US9226918B2 (en) * 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
    WO2010099490A2 (en) 2009-02-27 2010-09-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
    US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
    CA2760186A1 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
    US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
    US10010272B2 (en) 2010-05-27 2018-07-03 Profusa, Inc. Tissue-integrating electronic apparatus
    US9517023B2 (en) * 2009-06-01 2016-12-13 Profusa, Inc. Method and system for directing a localized biological response to an implant
    WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
    CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
    AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
    CA2776474A1 (en) 2009-10-02 2011-04-07 Foamix Ltd. Topical tetracycline compositions
    US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
    EP2485730A1 (en) 2009-10-09 2012-08-15 Nuvo Research Inc. Topical formulation comprising etoricoxib and a zwitterionic surfactant
    US8439896B2 (en) * 2009-11-13 2013-05-14 The Invention Science Fund I, Llc Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
    US8888761B2 (en) * 2009-11-13 2014-11-18 The Invention Science Fund I, Llc Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
    US8894630B2 (en) * 2009-11-13 2014-11-25 The Invention Science Fund I, Llc Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
    CN103491778B (en) 2010-04-13 2017-05-31 雷尔玛达治疗股份有限公司 1-methyl -N- (2,6-dimethylphenyl) -2-piperidinecarboxamide skin compositions and methods of use with drugs
    AU2011249043B2 (en) * 2010-05-04 2015-07-09 Nexmed Holdings, Inc. Compositions of small molecule therapeutics
    US20120022033A1 (en) * 2010-07-23 2012-01-26 Biosante Pharmaceuticals, Inc. Methods for decreasing cardiovascular risk in postmenopausal women
    WO2012037193A2 (en) 2010-09-17 2012-03-22 Brassica Protection Products Llc Formulations for treatment with glucosinolate
    US20120265034A1 (en) 2010-10-06 2012-10-18 Wisniewski Natalie A Tissue-integrating sensors
    EP2606895A4 (en) * 2010-10-12 2014-04-02 Univ Wuhan Transdermal absorption patch of antiviral drug and its preparation method
    SE535588C2 (en) * 2010-10-29 2012-10-02 Redsense Medical Ab The detection of blood leakage by detecting the presence of volatile substances
    JP2013543004A (en) 2010-11-18 2013-11-28 ホワイト マウンテン ファーマ,インコーポレイテッド For treating chronic or unresolvable pain in a subject, and / or methods for increasing pain threshold, and pharmaceutical compositions for use in this
    EP2675454A1 (en) 2011-02-15 2013-12-25 Eli Lilly And Co. Methods for controlling pain in equines using a transdermal solution of fentanyl
    ES2688288T3 (en) 2011-02-15 2018-10-31 Elanco Us Inc. Procedures to control pain in dogs using a transdermal fentanyl solution
    US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
    US8394359B1 (en) * 2011-08-26 2013-03-12 Michael P. O'Neil Tattoo removal system and method
    MX2014015900A (en) 2012-06-18 2015-07-17 Therapeuticsmd Inc Progesterone formulations.
    EP2782584A4 (en) 2011-11-23 2015-12-23 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
    US20150133421A1 (en) 2012-11-21 2015-05-14 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
    US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
    CN103181956B (en) * 2011-12-30 2015-04-29 天津市山佳医药科技有限公司 Percutaneous absorption plaster for treating degenerative osteoarthropathy
    US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
    US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
    US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
    MX2015003643A (en) 2012-09-21 2016-04-06 Intensity Therapeutics Inc Method of treating cancer.
    US9694050B2 (en) 2012-10-21 2017-07-04 University Of Rochester THY1 (CD90) as a novel therapy to control adipose tissue accumulation
    EP2916814A4 (en) 2012-11-06 2016-05-18 Colabs Internat Corp Composition containing a cellulose derived capsule with a sunscreen
    US10322301B2 (en) 2012-11-06 2019-06-18 CoLabs International Corporation Compositions containing a cellulose derived capsule with a sunscreen active agent
    US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
    US20170216310A1 (en) 2014-10-22 2017-08-03 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
    EP2953628B1 (en) 2013-02-11 2018-10-10 Glycanova AS Basidiomycete-derived cream for treatment of skin diseases
    CN108013881A (en) 2013-03-14 2018-05-11 普罗菲尤萨股份有限公司 Method and device for correcting optical signals
    US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
    BR112015029988A2 (en) 2013-06-06 2017-07-25 Profusa Inc apparatus and methods for detecting optical signals from sensors implanted
    USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
    USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
    US9227044B2 (en) 2013-12-09 2016-01-05 Amneal Pharmaceuticals Llc Applicator for applying a fluid to a surface
    USD752287S1 (en) 2013-12-09 2016-03-22 Amneal Pharmaceuticals Llc Applicator for applying a liquid to a surface
    KR101934169B1 (en) * 2013-12-24 2018-12-31 더 프록터 앤드 갬블 캄파니 Cosmetic compositions and methods providing enhanced penetration of skin care actives
    US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
    KR20150134176A (en) 2014-05-21 2015-12-01 에스케이케미칼주식회사 Transdermal composition comprising rotigotine with improved the stability
    EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
    US20160022643A1 (en) * 2014-07-22 2016-01-28 Professional Compounding Centers Of America Oral Transmucosal Compositions including Aromatase Inhibitors for Low Testosterone Levels in Men
    US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
    SG11201707784XA (en) 2015-03-23 2017-10-30 Biopharmx Inc Pharmaceutical tetracycline composition for dermatological use
    US20160307158A1 (en) * 2015-04-16 2016-10-20 Linkedin Corporation Aggregating and transforming user actions into social signal features for a job recommendation engine
    CA2958794C (en) 2015-07-08 2018-10-23 Triple Hair Inc. Composition comprising resveratrol and melatonin for reducing hair loss and/or increasing hair regrowth
    US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
    KR20180126582A (en) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 Steroid hormone pharmaceutical composition
    US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
    WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals

    Citations (10)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    EP0189861A2 (en) * 1985-01-26 1986-08-06 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
    US4663157A (en) * 1985-02-28 1987-05-05 The Proctor & Gamble Company Sunscreen compositions
    US4699779A (en) * 1986-02-18 1987-10-13 Victor Palinczar Waterproof sunscreen compositions
    US4975272A (en) * 1976-11-10 1990-12-04 Voyt Walter F Method of and composition for the prevention of solar radiation exposure-induced formation of carcinogenic skin lipid degradation products
    US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
    US5192534A (en) * 1988-12-30 1993-03-09 L'oreal Composition for inducing and stimulating hair growth and/or retarding its loss, based on pyrimidine derivatives and sunscreens
    EP0552405A1 (en) * 1992-01-24 1993-07-28 LINTEC Corporation A percutaneous absorption promoter, a tape plaster and a method of promoting percutaneous absorption
    US5426210A (en) * 1991-05-09 1995-06-20 Shiseido Co., Ltd. Adduct of cinnamic acid and glycerin, ultraviolet absorbent and external preparation for skin
    WO1996017624A1 (en) * 1994-12-07 1996-06-13 Warner-Lambert Company Sunscreen-wound healing composition
    WO1996041613A1 (en) * 1995-06-08 1996-12-27 Lancaster-Group Gmbh Multi-phase light screening agent, process for its production and for its application to the skin

    Family Cites Families (141)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    BE555319A (en) * 1956-03-21 1900-01-01
    GB867904A (en) * 1959-07-27 1961-05-10 Farmilai Farmaceutici Soc Spraying apparatus
    US3211250A (en) * 1962-12-21 1965-10-12 Garfield A Wood Seat-actuated brake and switch arrangement for motor vehicles
    US3306252A (en) * 1963-12-03 1967-02-28 Johnson & Johnson Shielded aerosol medicament dispenser
    US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
    US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
    US3598122B1 (en) 1969-04-01 1982-11-23
    US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
    US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
    AT330643B (en) * 1971-04-23 1976-07-12 Laake Oy aerosol device
    US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
    US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
    US3742951B1 (en) 1971-08-09 1982-11-23
    US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
    BE795384A (en) 1972-02-14 1973-08-13 Ici Ltd dressings
    US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
    US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
    US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
    US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
    US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
    US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
    DK534178A (en) 1977-12-16 1979-06-17 Interx Research Corp Anticholinergic agents with effect sektrtionshaemmende
    JPS5729448B2 (en) 1978-11-06 1982-06-23
    US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
    US4954487A (en) 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
    US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
    US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
    US4310511A (en) * 1980-10-02 1982-01-12 Massachusetts General Hospital Sunscreen compositions containing Δ5,7 steroidal dienes
    US4938951A (en) * 1980-12-30 1990-07-03 Union Carbide Chemicals And Plastics Company Inc. Potentiation of topical compositions wherein a uniform microdispersion of active agent is formed
    US4440777A (en) 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
    US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
    JPH058169B2 (en) * 1983-10-20 1993-02-01 Hisamitsu Pharmaceutical Co
    US4563346A (en) * 1984-03-14 1986-01-07 Charles Of The Ritz Group Ltd. Topical delivery system and skin treatment compositions employing such system
    US5008111A (en) * 1984-10-11 1991-04-16 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
    US4824676A (en) * 1984-10-11 1989-04-25 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
    JPS61268631A (en) 1985-05-22 1986-11-28 Showa Denko Kk Dermal external drug having improved percutaneous absorbability
    DE3522550A1 (en) 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab Sprayable pharmaceutical preparation for topical application
    US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
    US5256647A (en) 1986-01-31 1993-10-26 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
    AU592629B2 (en) 1986-01-31 1990-01-18 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes and their uses
    LU86368A1 (en) * 1986-03-24 1987-11-11 Oreal A method for preparing and dispensing a product comprising at least two components, and device for its implementation
    US4820724A (en) 1986-03-31 1989-04-11 University Of Southern California Dual phase solvent carrier system
    US5196410A (en) 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
    US4861764A (en) 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
    US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
    US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
    EP0281395A3 (en) * 1987-03-06 1990-10-10 Richardson-Vicks, Inc. Improved skin moisturizing emulsions
    BE1000381A4 (en) 1987-03-13 1988-11-16 Pharlyse Sa PHARMACEUTICAL PREPARATION BASED indomethacin.
    US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
    US5082656A (en) * 1987-04-30 1992-01-21 Abbott Laboratories Topical antibacterial compositions containing penetration enchancers
    US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
    US5100918A (en) * 1989-05-25 1992-03-31 Sterling Drug, Inc. Prevention or treatment of sunburn using the S(+) isomer of ibuprofen
    US4946671A (en) * 1987-10-22 1990-08-07 The Procter & Gamble Company Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent
    US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
    IE62871B1 (en) * 1988-03-08 1995-03-08 Warner Lambert Co Compositions with enhanced penetration
    US5017365A (en) * 1988-05-09 1991-05-21 Solarcare Technologies Corporation Sunscreen composition and applicator system
    US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
    US5164406A (en) 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
    US5487989A (en) 1988-08-31 1996-01-30 Bioenergy International, L.C. Ethanol production by recombinant hosts
    US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
    US4917882A (en) * 1989-03-16 1990-04-17 Amway Corporation Gel-type sunscreen composition
    US4959205A (en) * 1989-03-23 1990-09-25 Collagen Corporation Composition and method for treatment of dermal inflammation
    US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
    IT8920486D0 (en) * 1989-05-12 1989-05-12 Isf Spa Pharmaceutical compositions.
    EP0404334B1 (en) * 1989-05-19 1994-02-02 Beecham Group p.l.c. Aerosol compositions for topical application
    FR2648133B1 (en) * 1989-06-08 1992-02-21 Sanofi Sa Lauramides n-substituted, their preparation and compositions containing them
    US5219877A (en) * 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
    US5023085A (en) 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
    WO1991007944A1 (en) 1989-12-04 1991-06-13 Richardson-Vicks, Inc. Photoprotective compositions
    US5115805A (en) 1990-02-23 1992-05-26 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
    SG45171A1 (en) * 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
    EP0474597B1 (en) * 1990-09-05 1997-08-06 Ciba Specialty Chemicals Holding Inc. Diphenyl compounds as inhibitors of the arachidonic acid pathway and their use in pharmaceutical compositions
    US5202125A (en) 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
    TW213418B (en) 1991-05-02 1993-09-21 Kuko Seiyaku Kk
    TW206918B (en) 1991-05-11 1993-06-01 Kuko Seiyaku Kk
    US5212199A (en) * 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
    WO1993000873A1 (en) * 1991-07-03 1993-01-21 Sano Corporation Composition and method for transdermal delivery of diclofenac
    US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
    EG20380A (en) 1991-10-16 1999-02-28 Richardson Vicks Inc Enhanced skin penetration system for improved topical delivery of drugs
    WO1993010755A1 (en) 1991-11-25 1993-06-10 Richardson-Vicks, Inc. Compositions for regulating skin wrinkles and/or skin atrophy
    WO1993010756A1 (en) 1991-11-25 1993-06-10 Richardson-Vicks, Inc. Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
    AU671811B2 (en) 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion
    US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
    CA2101496A1 (en) 1992-07-31 1994-02-01 Masao Kobayashi Base for transdermal administration
    JP3453843B2 (en) * 1993-06-08 2003-10-06 ソニー株式会社 Disk device
    FR2708000B1 (en) * 1993-07-22 1995-08-25 Pechiney Aluminium Aluminum electrorefined low grade uranium, thorium and rare earths.
    US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
    DE4334553C2 (en) 1993-10-11 1998-05-20 Synopharm Gmbh Pharmazeutische Liquid pharmaceutical system for percutaneous administration
    FR2714602B1 (en) * 1993-12-30 1996-02-09 Oreal anti-acne composition for the simultaneous treatment of the surface and deep layers of the skin, in use.
    DE4400770C1 (en) * 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Plaster containing an active substance for delivery of oestradiol with at least one penetration enhancer, method of producing it and its use
    US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
    US5505935A (en) * 1994-05-09 1996-04-09 Elizabeth Arden Company, Division Of Conopco, Inc. Sunscreen compositions
    US5508168A (en) * 1994-05-16 1996-04-16 Hoffmann-La Roche Inc. Methods and reagents for the detection of herpes simplex virus, treponema pallidum, and haemophilus ducreyi
    US5449519C1 (en) * 1994-08-09 2001-05-01 Revlon Consumer Prod Corp Cosmetic compositions having keratolytic and anti-acne activity
    GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
    FR2732223B1 (en) * 1995-03-30 1997-06-13 Sanofi Sa A pharmaceutical composition for transdermal administration
    AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
    US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
    US6998138B2 (en) * 1996-02-19 2006-02-14 Acrux Dds Pty. Ltd. Topical delivery of anti-alopecia agents
    US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
    US6916487B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
    US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
    US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
    US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
    AUPO379596A0 (en) * 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
    US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
    IT1294748B1 (en) 1997-09-17 1999-04-12 Permatec Tech Ag A formulation for a transdermal device
    US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
    US6101716A (en) * 1998-02-12 2000-08-15 Schulz; Steven L. Evaporative cooler solar retrofit kit
    ES2193726T3 (en) * 1998-08-04 2003-11-01 Jago Res Ag Medicinal aerosol formulations.
    EP1150661B1 (en) 1999-02-05 2003-10-22 Cipla Ltd. Topical sprays comprising a film forming composition
    US6399093B1 (en) * 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
    WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
    AU4515001A (en) 1999-12-02 2001-06-18 Regents Of The University Of Michigan, The Compositions and methods for locally treating inflammatory diseases
    US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
    US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
    IN191090B (en) 2000-08-29 2003-09-20 Ranbanx Lab Ltd A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
    US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
    US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
    PL373593A1 (en) 2002-03-15 2005-09-05 Unimed Pharmaceuticals, Inc. Androgen pharmaceutical composition and method for treating depression
    PT1322336E (en) 2000-08-30 2013-08-05 Unimed Pharmaceuticals Llc Method of increasing testosterone and related steroid concentrations in women
    PL205279B1 (en) 2000-08-30 2010-03-31 Unimed Pharmaceuticals, Inc. Method for treating erectile dysfunction and increasing libido in men
    US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
    CA2431566A1 (en) * 2000-12-11 2002-07-18 Testocreme, Llc Topical testosterone formulations and associated methods
    US20030199584A1 (en) 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
    US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
    US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
    NZ537360A (en) * 2002-06-25 2006-09-29 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
    FR2851470B1 (en) * 2003-02-20 2007-11-16 Besins Int Belgique A pharmaceutical composition for transdermal or transmucosal administration
    US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
    CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
    US6923226B2 (en) * 2003-07-01 2005-08-02 Patrick Wesley Bartlett Device for preventing entry of an unleaded gas fill nozzle in a diesel fuel filler neck
    US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
    US20050025833A1 (en) 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
    US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
    BRPI0414551A (en) 2003-10-10 2006-10-31 Antares Pharma Ipl Ag transdermal or transmucosal pharmaceutical formulation and method of delaying or inhibiting crystallization of an active agent
    CA2546404A1 (en) 2003-11-19 2005-06-02 Acrux Dds Pty Ltd. Method and composition for treatment or prophylaxis of amyloidosis disorders
    US20050123575A1 (en) 2003-12-03 2005-06-09 Eilon Asculai Spreadable compositions for topical use, an improved process of making same and methods of using same
    AU2005218665A1 (en) * 2004-03-03 2005-09-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
    CA2609330A1 (en) * 2005-05-25 2006-11-30 Transcept Pharmaceuticals, Inc. Solid compositions and methods for treating middle-of-the night insomnia
    US8435944B2 (en) * 2005-06-03 2013-05-07 Acrux Dds Pty Ltd. Method and composition for transdermal drug delivery

    Patent Citations (10)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US4975272A (en) * 1976-11-10 1990-12-04 Voyt Walter F Method of and composition for the prevention of solar radiation exposure-induced formation of carcinogenic skin lipid degradation products
    EP0189861A2 (en) * 1985-01-26 1986-08-06 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
    US4663157A (en) * 1985-02-28 1987-05-05 The Proctor & Gamble Company Sunscreen compositions
    US4699779A (en) * 1986-02-18 1987-10-13 Victor Palinczar Waterproof sunscreen compositions
    US5192534A (en) * 1988-12-30 1993-03-09 L'oreal Composition for inducing and stimulating hair growth and/or retarding its loss, based on pyrimidine derivatives and sunscreens
    US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
    US5426210A (en) * 1991-05-09 1995-06-20 Shiseido Co., Ltd. Adduct of cinnamic acid and glycerin, ultraviolet absorbent and external preparation for skin
    EP0552405A1 (en) * 1992-01-24 1993-07-28 LINTEC Corporation A percutaneous absorption promoter, a tape plaster and a method of promoting percutaneous absorption
    WO1996017624A1 (en) * 1994-12-07 1996-06-13 Warner-Lambert Company Sunscreen-wound healing composition
    WO1996041613A1 (en) * 1995-06-08 1996-12-27 Lancaster-Group Gmbh Multi-phase light screening agent, process for its production and for its application to the skin

    Also Published As

    Publication number Publication date
    US6964777B2 (en) 2005-11-15
    HK1101553A1 (en) 2010-10-29
    US8071075B2 (en) 2011-12-06
    ES2348313T3 (en) 2010-12-02
    JP2007326867A (en) 2007-12-20
    LU91973I2 (en) 2012-06-04
    DE69735804T2 (en) 2006-12-14
    JP4213211B2 (en) 2009-01-21
    DK1674068T3 (en) 2009-02-09
    AT410136T (en) 2008-10-15
    LU91971I2 (en) 2012-06-04
    DE122012000019I1 (en) 2012-06-14
    KR100528602B1 (en) 2007-03-15
    US20080152597A1 (en) 2008-06-26
    CA2244089A1 (en) 1997-08-21
    NZ330942A (en) 1999-11-29
    US20020028235A1 (en) 2002-03-07
    PT901368E (en) 2006-09-29
    HK1087355A1 (en) 2009-01-09
    DE69739931D1 (en) 2010-08-19
    DE122012000020I1 (en) 2012-06-14
    DK1769785T3 (en) 2010-10-25
    CA2244089C (en) 2009-06-02
    WO1997029735A1 (en) 1997-08-21
    DE69739037D1 (en) 2008-11-20
    JP2000504697A (en) 2000-04-18
    EP1674068A1 (en) 2006-06-28
    AT324865T (en) 2006-06-15
    DE69735804D1 (en) 2006-06-08
    EP1769785A1 (en) 2007-04-04
    ES2314538T3 (en) 2009-03-16
    US20070077288A1 (en) 2007-04-05
    US20040009214A1 (en) 2004-01-15
    US7387789B2 (en) 2008-06-17
    EP0901368A4 (en) 2000-01-26
    KR19990087057A (en) 1999-12-15
    AUPN814496A0 (en) 1996-03-14
    EP1674068B1 (en) 2008-10-08
    PT1674068E (en) 2008-12-11
    EP1769785B1 (en) 2010-07-07
    US6818226B2 (en) 2004-11-16
    US7438203B2 (en) 2008-10-21
    LU91972I2 (en) 2012-06-04
    US20040146469A1 (en) 2004-07-29
    DE122012000021I1 (en) 2012-07-12
    US6299900B1 (en) 2001-10-09
    AT472997T (en) 2010-07-15
    HK1018884A1 (en) 2006-08-04
    AU1713497A (en) 1997-09-02
    AU706967B2 (en) 1999-07-01
    US20070071803A1 (en) 2007-03-29
    PT1769785E (en) 2010-08-26
    DK0901368T3 (en) 2006-09-04
    EP0901368A1 (en) 1999-03-17
    US20080131494A1 (en) 2008-06-05
    ES2262173T3 (en) 2006-11-16

    Similar Documents

    Publication Publication Date Title
    Ranade Drug delivery systems. 6. Transdermal drug delivery
    US4230105A (en) Transdermal delivery of drugs
    US5665378A (en) Transdermal therapeutic formulation
    US8481091B2 (en) Pharmaceutical compositions
    US8529939B2 (en) Mucoadhesive drug delivery devices and methods of making and using thereof
    EP1150661B1 (en) Topical sprays comprising a film forming composition
    EP0828516B1 (en) Skin permeation enhancer compositions using acyl lactylates
    CA1276111C (en) Transdermal verapamil delivery device
    JP3026602B2 (en) Vegetable oil-based skin permeation enhancer compositions and methods and systems related thereto
    US4883660A (en) Gel bases for pharmaceutical compositions
    RU2161957C2 (en) Film-forming pharmaceutical composition for transdermal administration
    EP0091964B2 (en) Base composition for preparing medicine for external application, medicinal composition for external application, and method for accelerating percutaneous absorption of medicinal agent
    JP2903708B2 (en) External aerosol agent
    US6432415B1 (en) Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
    EP0303713B1 (en) Percutaneous absorption promoter and dermatologic preparation for external use
    US20090069364A1 (en) Pharmaceutical compositions of 5-alpha-reductase inhibitors and methods of use thereof
    US6835392B2 (en) Dual enhancer composition for topical and transdermal drug delivery
    US6342250B1 (en) Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
    KR0143916B1 (en) Method for reducing skin irritation associated with drug/penetration enhancer compositions
    US20020131994A1 (en) Non-irritating formulation for the transdermal delivery of substances
    US20070071688A1 (en) Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
    US5376377A (en) Transdermal contraceptive formulations, methods and devices
    US5164189A (en) Single layer transdermal drug administration system
    EP0535327B1 (en) Pharmaceutical composition containing felbinac
    EP1510213B1 (en) Penetration enhancing and irritation reducing systems comprising testosterone

    Legal Events

    Date Code Title Description
    17P Request for examination filed

    Effective date: 19980911

    AK Designated contracting states:

    Kind code of ref document: A1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    AK Designated contracting states:

    Kind code of ref document: A4

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    A4 Despatch of supplementary search report

    Effective date: 19991209

    17Q First examination report

    Effective date: 20020918

    RAP1 Transfer of rights of an ep published application

    Owner name: ACRUX DDS PTY LTD

    RIC1 Classification (correction)

    Ipc: 7A 61K 9/08 B

    Ipc: 7A 61K 9/06 A

    Ipc: 7A 61K 9/10 B

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: FG4D

    AK Designated contracting states:

    Kind code of ref document: B1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

    Ref country code: IT

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20060503

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: EP

    REF Corresponds to:

    Ref document number: 69735804

    Country of ref document: DE

    Date of ref document: 20060608

    Kind code of ref document: P

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    REG Reference to a national code

    Ref country code: HK

    Ref legal event code: GR

    Ref document number: 1018884

    Country of ref document: HK

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: NV

    Representative=s name: DR. LUSUARDI AG

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: TRGR

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: T3

    REG Reference to a national code

    Ref country code: GR

    Ref legal event code: EP

    Ref document number: 20060402465

    Country of ref document: GR

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: SC4A

    Effective date: 20060720

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FG2A

    Ref document number: 2262173

    Country of ref document: ES

    Kind code of ref document: T3

    ET Fr: translation filed
    26N No opposition filed

    Effective date: 20070206

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: 8364

    Ref document number: 69735804

    Country of ref document: DE

    Kind code of ref document: T

    REG Reference to a national code

    Ref country code: FI

    Ref legal event code: SPCF

    Spc suppl protection certif: C20120015

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: CP

    Free format text: PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006

    Spc suppl protection certif: 12C0025

    Filing date: 20120406

    REG Reference to a national code

    Ref country code: NL

    Ref legal event code: KC1

    Free format text: PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006

    Spc suppl protection certif: C300523

    Filing date: 20120406

    Extension date: 20220218

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: SPCF

    Free format text: PRODUCT NAME: FENTANYL; REG. NO/DATE: EU/2/11/127/001 20111006

    Spc suppl protection certif: 1290009-8

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: CTFF

    Free format text: PRODUCT NAME: FENTANYL; REGISTERED: UK EU/2/11/127/001 20111006

    Spc suppl protection certif: SPC/GB12/013

    Filing date: 20120403

    Ref country code: IE

    Ref legal event code: SPCF

    Free format text: PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006

    Spc suppl protection certif: 2012/013

    Filing date: 20120403

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: CR

    Free format text: PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE IN FRANCE: EU/2/11/127/001 DU 20111006; REGISTRATION NO/DATE AT EEC: EU/2/11/127/001 DU 20111006

    Spc suppl protection certif: 12C0025

    Filing date: 20120406

    Ref country code: FR

    Ref legal event code: CP

    Effective date: 20120412

    Ref country code: FR

    Ref legal event code: CP

    Free format text: PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006

    Spc suppl protection certif: 12C0025

    Filing date: 20120406

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: CTFF

    Spc suppl protection certif: CA 2012 00010

    Filing date: 20120403

    Expiry date: 20220219

    REG Reference to a national code

    Ref country code: LU

    Ref legal event code: CCP

    Free format text: 91973, EXPIRES: 20220219

    Spc suppl protection certif: 91973

    Expiry date: 20220219

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R065

    Ref document number: 69735804

    Country of ref document: DE

    Kind code of ref document: T

    Free format text: PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006

    Spc suppl protection certif: 122012000020

    Filing date: 20120403

    Expiry date: 20170220

    Effective date: 20120423

    REG Reference to a national code

    Ref country code: NL

    Ref legal event code: SPCR

    Free format text: PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006

    Spc suppl protection certif: C300523

    Filing date: 20120406

    Extension date: 20220218

    Effective date: 20140721

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: SPCR

    Free format text: PRODUCT NAME: FENTANYL

    Spc suppl protection certif: 1290009-8

    Effective date: 20150424

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: PLFP

    Year of fee payment: 20

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: CTFW

    Free format text: PRODUCT NAME: FENTANYL; REGISTERED: UK EU/2/11/127/001 20111006

    Spc suppl protection certif: SPC/GB12/013

    Filing date: 20120403

    PGFP Postgrant: annual fees paid to national office

    Ref country code: LU

    Payment date: 20160217

    Year of fee payment: 20

    REG Reference to a national code

    Ref country code: FI

    Ref legal event code: SPCG

    Spc suppl protection certif: 446

    Extension date: 20220219

    PGFP Postgrant: annual fees paid to national office

    Ref country code: IT

    Payment date: 20160218

    Year of fee payment: 20

    Ref country code: DK

    Payment date: 20160217

    Year of fee payment: 20

    Ref country code: CH

    Payment date: 20160218

    Year of fee payment: 20

    Ref country code: ES

    Payment date: 20160215

    Year of fee payment: 20

    Ref country code: DE

    Payment date: 20160226

    Year of fee payment: 20

    Ref country code: IE

    Payment date: 20160211

    Year of fee payment: 20

    Ref country code: MC

    Payment date: 20160219

    Year of fee payment: 20

    PGFP Postgrant: annual fees paid to national office

    Ref country code: FI

    Payment date: 20160216

    Year of fee payment: 20

    Ref country code: FR

    Payment date: 20160225

    Year of fee payment: 20

    Ref country code: BE

    Payment date: 20160224

    Year of fee payment: 20

    Ref country code: GR

    Payment date: 20160210

    Year of fee payment: 20

    Ref country code: GB

    Payment date: 20160211

    Year of fee payment: 20

    Ref country code: SE

    Payment date: 20160222

    Year of fee payment: 20

    Ref country code: NL

    Payment date: 20160225

    Year of fee payment: 20

    Ref country code: AT

    Payment date: 20160225

    Year of fee payment: 20

    Ref country code: PT

    Payment date: 20160202

    Year of fee payment: 20

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: SPCR

    Free format text: PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006

    Spc suppl protection certif: 2012/013

    Filing date: 20120403

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: CTFG

    Free format text: PRODUCT NAME: FENTANYL; REG. NO/DATE: EU/2/11/127/001 20111011

    Spc suppl protection certif: CR 2012 00010

    Filing date: 20120403

    Expiry date: 20170219

    Extension date: 20220219

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R071

    Ref document number: 69735804

    Country of ref document: DE

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: EUP

    Effective date: 20170219

    REG Reference to a national code

    Ref country code: NL

    Ref legal event code: MK

    Effective date: 20170218

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PL

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: PE20

    Expiry date: 20170218

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: MK9A

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: EUG

    REG Reference to a national code

    Ref country code: AT

    Ref legal event code: MK07

    Ref document number: 324865

    Country of ref document: AT

    Kind code of ref document: T

    Effective date: 20170219

    REG Reference to a national code

    Ref country code: GR

    Ref legal event code: MA

    Ref document number: 20060402465

    Country of ref document: GR

    Effective date: 20170220

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FD2A

    Effective date: 20170526

    PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20170228

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20170219

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20170218

    PG25 Lapsed in a contracting state announced via postgrant inform. from nat. office to epo

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20170220

    REG Reference to a national code

    Ref country code: AT

    Ref legal event code: SPCL

    Ref document number: 324865

    Country of ref document: AT

    Kind code of ref document: T

    Free format text: PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006

    Spc suppl protection certif: 12/2012

    Filing date: 20120403

    Expiry date: 20170219

    Extension date: 20220219

    Effective date: 20170219

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: CTFL

    Free format text: PRODUCT NAME: FENTANYL; REG. NO/DATE: EU/2/11/127/001 20111011

    Spc suppl protection certif: CR 2012 00010

    Filing date: 20120403

    Expiry date: 20170219

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: SPCL

    Free format text: PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006

    Spc suppl protection certif: 12C0025

    Filing date: 20120406

    REG Reference to a national code

    Ref country code: BE

    Ref legal event code: SPCF

    Free format text: PRODUCT NAME: FENTANYL; AUTHORISATION NUMBER AND DATE: EU/2/11/127/001 20111011

    Spc suppl protection certif: 2012C/013

    Filing date: 20120404

    Expiry date: 20170219

    Extension date: 20220219

    Ref country code: BE

    Ref legal event code: SPCL

    Free format text: PRODUCT NAME: FENTANYL; AUTHORISATION NUMBER AND DATE: EU/2/11/127/001 20111011

    Spc suppl protection certif: 2012C/013

    Extension date: 20220219

    Effective date: 20170228

    REG Reference to a national code

    Ref country code: BE

    Ref legal event code: SPCD

    Free format text: PRODUCT NAME: FENTANYL; AUTHORISATION NUMBER AND DATE: EU/2/11/127/001 20111011

    Spc suppl protection certif: 2012C/013

    Extension date: 20220219

    Effective date: 20180904